Erythropoietin variants and uses thereof

JP2023550742A5Active Publication Date: 2024-11-22CHULABHORN FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529983
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-18
Filing Date
2021-11-18
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Current treatments for anemia, such as those using recombinant human erythropoietin (rHuEPO), often induce an immune response and can lead to conditions like pure red cell aplasia (PRCA), particularly in individuals with specific HLA alleles like HLA-DRB1*09, necessitating new approaches to reduce immunogenicity while maintaining biological activity.

Method used

Development of EPO molecules with targeted mutations at specific positions, such as 74-82, 102-116, and 142-153, to reduce immunogenicity and enhance serum half-life, thereby minimizing immune responses and improving efficacy in subjects at risk.

Benefits of technology

The modified EPO molecules exhibit reduced immunogenicity, maintaining biological activity and serum half-life, effectively treating anemia and preventing conditions like PRCA in susceptible populations.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed are human erythropoietin (EPO) variants. The EPO variants contain one or more mutations that reduce immunogenicity. The EPO variants can be used to treat or prevent EPO-related disorders, such as anemia.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 63 / 115,208, filed on 18 November 2020. The contents of the aforementioned application are incorporated herein by reference in their entirety.

[0002] Sequence List This application includes an electronically submitted sequence listing in ASCII format, the entirety of which is incorporated herein by reference. The ASCII copy, created on November 12, 2021, is named C2238-7000WO_SL.txt and has a size of 51,498 bytes. [Background technology]

[0003] Erythropoietin (EPO) is a protein hormone produced by the kidneys that plays an essential role in the production and maturation of red blood cells (RBCs), which carry oxygen from the lungs to the rest of the body. Recombinant human erythropoietin (rHuEPO) can be administered to patients with insufficient hemoglobin levels, such as those with anemia, and / or those unable to produce sufficient amounts of endogenous EPO, such as those with chronic kidney disease (CKD), HIV infection, or malignant tumors, and those dependent on dialysis. rHuEPO has also been used to promote red blood cell production after surgery, chemotherapy, and transplantation (Ng, T. et al. Postgrad. Med. J. (2003) 79:367-376). Treatment with rHuEPO has been shown to improve the quality of life (QoL) in individuals with anemia (Horl, et al. Nephrol. Dial. Transplant (1996) 11:246-250; Kaneko, Y. et al. Kidney Int. (2003) 63:1086-1093). However, despite advances in the treatment of anemia with rHuEPO, the need for developing new approaches, including novel agents (e.g., EPO polypeptide variants), to treat and prevent anemia, including anemia or related disorders associated with EPO deficiency, remains unmet. [Overview of the Initiative]

[0004] In one embodiment, the present disclosure features an EPO molecule having a mutation at a position disclosed herein, for example, an EPO molecule having one or more of the functional properties disclosed herein.

[0005] In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 12-152 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 74-82, 102-116, or 142-153 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 74-82 or 102-116 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 74-82 or 142-153 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 102-116 or 142-153 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 74-82 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 102-116 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 102-110 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 108-116 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 142-153 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 142-150 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 145-153 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at a position corresponding to any of positions 74, 75, 76, 77, 79, 80, 81, 82, 102, 105, 106, 109, 111, 112, 113, 114, 115, 116, 142, 145, 146, 148, 149, 152, or 153 of SEQ ID NO: 1. In one embodiment, the EPO molecule contains a mutation at any of the positions corresponding to positions 12, 15, 67, 70, 74, 102, 105, 106, 109, 114, 146, 149, or 152 of SEQ ID NO: 1.

[0006] In one embodiment, the EPO molecule includes multiple mutations (e.g., multiple mutations disclosed herein) at multiple positions (e.g., multiple mutations disclosed herein). In one embodiment, the EPO molecule further includes a second mutation at a second position disclosed herein. In one embodiment, the EPO molecule further includes a third mutation at a third position disclosed herein. In one embodiment, the EPO molecule further includes a fourth mutation at a fourth position disclosed herein. In one embodiment, the EPO molecule further includes a fifth mutation at a fifth position disclosed herein. In one embodiment, the EPO molecule further includes a sixth mutation at a sixth position disclosed herein.

[0007] In one embodiment, the EPO molecule contains a mutation at the position corresponding to position 12 of SEQ ID NO: 1. In one embodiment, the mutation is an L12A substitution. In another embodiment, the mutation is an L12I substitution.

[0008] In one embodiment, the EPO molecule contains a mutation at the position corresponding to position 15 of SEQ ID NO: 1. In one embodiment, the mutation is a Y15I substitution. In another embodiment, the mutation is a Y15W substitution.

[0009] In one embodiment, the EPO molecule contains a mutation at the position corresponding to position 67 of SEQ ID NO: 1. In one embodiment, the mutation is an L67D substitution. In one embodiment, the mutation is an L67N substitution. In one embodiment, the mutation is an L67V substitution.

[0010] In one embodiment, the EPO molecule contains a mutation at the position corresponding to position 70 of SEQ ID NO: 1. In one embodiment, the mutation is an L70V substitution.

[0011] In one embodiment, the EPO molecule contains a mutation at the position corresponding to position 74 of SEQ ID NO: 1. In one embodiment, the mutation is a V74D substitution. In one embodiment, the mutation is a V74L substitution. In one embodiment, the mutation is a V74N substitution.

[0012] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 102 of SEQ ID NO: 1. In one embodiment, the mutation is an L102D substitution. In one embodiment, the mutation is an L102N substitution. In one embodiment, the mutation is an L102I substitution. In one embodiment, the mutation is an L102T substitution. In one embodiment, the mutation is an L102V substitution.

[0013] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 105 of SEQ ID NO: 1. In one embodiment, the mutation is an L105F substitution. In one embodiment, the mutation is an L105S substitution.

[0014] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 106 of SEQ ID NO: 1. In one embodiment, the mutation is a T106A substitution. In one embodiment, the mutation is a T106G substitution. In one embodiment, the mutation is a T106H substitution.

[0015] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 109 of SEQ ID NO: 1. In one embodiment, the mutation is an L109A substitution. In one embodiment, the mutation is an L109C substitution. In one embodiment, the mutation is an L109W substitution.

[0016] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 114 of SEQ ID NO: 1. In one embodiment, the mutation is an A114C substitution.

[0017] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 146 of SEQ ID NO: 1. In one embodiment, the mutation is an S146N substitution.

[0018] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 149 of SEQ ID NO: 1. In one embodiment, the mutation is an L149V substitution. In one embodiment, the mutation is an L149W substitution.

[0019] In one embodiment, the EPO molecule contains a mutation at a position corresponding to position 152 of SEQ ID NO: 1. In one embodiment, the mutation is a K152Q substitution.

[0020] In one embodiment, the EPO molecule contains mutations at positions corresponding to positions 67 and 102 of SEQ ID NO: 1. In one embodiment, the mutations are L67V and L102V substitutions. In one embodiment, the EPO molecule contains mutations at positions corresponding to positions 70, 74, and 102.

[0021] In one embodiment, the mutations are L70V, V74L and L102I substitutions.

[0022] In one embodiment, the EPO molecule contains mutations at positions corresponding to positions 67, 74, and 102. In one embodiment, the mutations are L67N, V74N and L102D substitutions. In one embodiment, the mutations are L67D, V74D and L102N substitutions.

[0023] In one embodiment, the EPO molecule contains mutations at positions corresponding to positions 12, 15, 105, and 149. In one embodiment, the mutations are L12A, Y15I, L105F and L149W substitutions. In one embodiment, the mutations are L12I, Y15W, L105S and L149V substitutions. In one embodiment, the EPO molecule contains mutations at positions corresponding to positions 109 and 114. In one embodiment, the mutations are L109C and A114C substitutions.

[0024] In one embodiment, the EPO molecule contains mutations at positions corresponding to positions 102, 105, 106 and 109. In one embodiment, the mutations are L102T, L105S, T106H and L109W substitutions. In one embodiment, the mutations are L102T, L105S, T106G and L109W substitutions.

[0025] In one embodiment, the EPO molecule contains mutations at positions corresponding to positions 146 and 152. In one embodiment, the mutations are S146N and K152Q substitutions.

[0026] In one embodiment, the EPO molecule has at least 80% homology to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has at least 85% homology to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has at least 90% homology to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has at least 95% homology to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has at least 96% homology to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has at least 97% homology to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has at least 98% homology to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has at least 99% homology to the amino acid sequence of SEQ ID NO: 1.

[0027] In one embodiment, in addition to the mutation(s)(s)(s)(s) disclosed herein, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 15 or less. In one embodiment, in addition to the mutation(s)(s)(s)(s) disclosed herein, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 10 or less. In one embodiment, in addition to the mutation(s)(s)(s)(s) disclosed herein, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 5 or less. In one embodiment, in addition to the mutation(s)(s)(s)(s) disclosed herein, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 4 or less. In one embodiment, in addition to the mutation(s)(s)(s)(s) disclosed herein, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 3 or less. In one embodiment, in addition to the mutation(s)(s)(s)(s) disclosed herein, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 2 or less.

[0028] In one embodiment, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 15 or below. In one embodiment, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 10 or below. In one embodiment, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 5 or below. In one embodiment, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 4 or below. In one embodiment, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 3 or below. In one embodiment, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 2 or below. In one embodiment, the EPO molecule differs from the amino acid sequence of SEQ ID NO: 1 at positions 1 or below.

[0029] In one embodiment, the EPO molecule contains an amino acid sequence that is identical to any of the amino acid sequences of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35, or an amino acid sequence that is identical to it by at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or an amino acid sequence that differs from it by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids.

[0030] In one embodiment, the EPO molecule contains any of the amino acid sequences of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35.

[0031] In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 3. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 5. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 7. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 9. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 11. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 13. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 15. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 17. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 19. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 21. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 23. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 25. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 27. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 29. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 31. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 33. In one embodiment, the EPO molecule contains or consists of the amino acid sequence of SEQ ID NO: 35.

[0032] In one embodiment, the EPO molecule, when determined, for example in vitro, ex vivo, or in vivo, has reduced immunogenicity in the subject compared to a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, the immunogenicity is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to the reference EPO molecule. In one embodiment, the subject possesses the HLA-DRB1*09 allele.

[0033] In one embodiment, the EPO molecule has the same or substantially the same biological activity as a reference EPO molecule, e.g., an EPO molecule containing the amino acid sequence of SEQ ID NO: 1, when determined, for example, in vitro, ex vivo, or in vivo. In one embodiment, the EPO molecule has biological activity that is 25%, 20%, 15%, 10%, 5%, or 2% or less lower than a reference EPO molecule, e.g., an EPO molecule containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, the biological activity is determined by an in vitro TF-1 growth assay.

[0034] In one embodiment, an EPO molecule may have more glycoforms, for example, at least one, two, three, four, or five more glycoforms, compared to a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, an EPO molecule may have six, seven, eight, nine, ten, or more glycoforms. In one embodiment, an EPO molecule may have seven, eight, or more glycoforms.

[0035] In one embodiment, the EPO molecule has the same or substantially the same serum half-life as a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has an increased serum half-life, for example, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, compared to a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, the EPO molecule has a decreased serum half-life, for example, by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% or less, compared to a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1.

[0036] In one embodiment, the EPO molecule includes a portion that extends the serum half-life of the EPO polypeptide. In one embodiment, the EPO molecule is a fusion protein. In one embodiment, the EPO molecule includes the Fc domain of IgG. In one embodiment, the Fc domain is covalently fused to the EPO polypeptide. In one embodiment, the N-terminus of the Fc domain is directly or indirectly covalently fused to the C-terminus of the EPO polypeptide.

[0037] In one embodiment, the EPO molecule is an isolated EPO molecule. In one embodiment, the EPO molecule is a recombinant EPO molecule. In one embodiment, the EPO molecule is a synthetic EPO molecule.

[0038] In one embodiment, the present disclosure features a pharmaceutical composition comprising an EPO molecule disclosed herein and a pharmaceutically acceptable carrier.

[0039] In one embodiment, the present disclosure features a preparation comprising an EPO molecule disclosed herein. In one embodiment, the preparation is suitable for therapeutic use.

[0040] In one embodiment, the present disclosure features a kit comprising the EPO molecule disclosed herein and instructions for use.

[0041] In one embodiment, the present disclosure features a nucleic acid encoding an EPO molecule disclosed herein.

[0042] In one embodiment, the disclosure features a nucleic acid comprising any of the nucleotide sequences of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36, or a nucleotide sequence that differs from them by 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides or less, or that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to them. In one embodiment, the nucleic acid comprises any of the nucleotide sequences of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36.

[0043] In one embodiment, the disclosure features a vector comprising a nucleic acid disclosed herein. In one embodiment, the vector comprises a promoter operably ligated to the nucleic acid.

[0044] In one embodiment, the present disclosure features cells comprising nucleic acids or vectors disclosed herein.

[0045] In one embodiment, the present disclosure features a method for producing an EPO molecule, comprising culturing cells disclosed herein under conditions that enable the expression of an EPO polypeptide, thereby producing an EPO molecule.

[0046] In one embodiment, the present disclosure features a method for treating a disorder, comprising administering an effective amount of the EPO molecule disclosed herein to the subject, thereby treating the disorder.

[0047] In one embodiment, the disorder is an EPO-related disorder, e.g., EPO deficiency or abnormality. In one embodiment, the disorder is anemia. In one embodiment, the anemia is related to or caused by chronic kidney disease (e.g., chronic renal failure), zidovudine treatment, chemotherapy, or surgery.

[0048] In one embodiment, the method further includes obtaining genotypic information to identify the HLA genotype in the subject, for example, the HLA-DRB1*09 genotype, and identifying that the presence of the HLA genotype indicates that the subject has or is at risk of having increased immunogenicity to EPO therapy. In one embodiment, the EPO molecule is administered in response to the acquisition of genotypic information.

[0049] In one embodiment, the subject possesses or has been determined to possess the HLA-DRB1*09 allele. In one embodiment, the subject has chronic kidney disease, HIV infection, or cancer. In one embodiment, the subject has received or has received zidovudine. In one embodiment, the subject has received or has received chemotherapy (e.g., myelosuppressive chemotherapy), surgery, or allogeneic RBC transfusion. In one embodiment, the subject possesses or has been determined to possess anti-EPO antibodies. In one embodiment, the subject has been administered a different recombinant human EPO (rHuEPO), for example, an EPO containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, administration of a different rHuEPO is discontinued or terminated.

[0050] In one embodiment, the present disclosure is a method for reducing an immunogenic response in a subject, comprising administering an effective amount of the EPO molecule disclosed herein to a subject in need thereof, thereby reducing the immunogenic response.

[0051] In one embodiment, the method further includes obtaining genotypic information to identify the HLA genotype in the subject, for example, the HLA-DRB1*09 genotype, and identifying that the presence of the HLA genotype indicates that the subject has or is at risk of having increased immunogenicity to EPO therapy. In one embodiment, the EPO molecule is administered in response to the acquisition of genotypic information.

[0052] In one embodiment, the subject possesses or has been determined to possess the HLA-DRB1*09 allele. In one embodiment, the subject has chronic kidney disease, HIV infection, or cancer. In one embodiment, the subject has received or has received zidovudine. In one embodiment, the subject has received or has received chemotherapy (e.g., myelosuppressive chemotherapy), surgery, or allogeneic RBC transfusion. In one embodiment, the subject possesses or has been determined to possess anti-EPO antibodies. In one embodiment, the subject has been administered a different recombinant human EPO (rHuEPO), for example, an EPO containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, administration of a different rHuEPO is discontinued or terminated.

[0053] In one embodiment, the present disclosure is a method for treating or preventing pure red cell aplasia (PRCA) in a subject, comprising administering an effective amount of the EPO molecule disclosed herein to a subject in need thereof, thereby treating or preventing PRCA.

[0054] In one embodiment, the method further includes obtaining genotypic information to identify the HLA genotype in the subject, for example, the HLA-DRB1*09 genotype, and identifying that the presence of the HLA genotype indicates that the subject has or is at risk of having increased immunogenicity to EPO therapy. In one embodiment, the EPO molecule is administered in response to the acquisition of genotypic information.

[0055] In one embodiment, the subject possesses or has been determined to possess the HLA-DRB1*09 allele. In one embodiment, the subject has chronic kidney disease, HIV infection, or cancer. In one embodiment, the subject has received or has received zidovudine. In one embodiment, the subject has received or has received chemotherapy (e.g., myelosuppressive chemotherapy), surgery, or allogeneic RBC transfusion. In one embodiment, the subject possesses or has been determined to possess anti-EPO antibodies. In one embodiment, the subject has been administered a different recombinant human EPO (rHuEPO), for example, an EPO containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, administration of a different rHuEPO is discontinued or terminated.

[0056] In one embodiment, the present disclosure is a method for reducing allogeneic red blood cell (RBC) transfusions in a subject, comprising administering an effective amount of the EPO molecule disclosed herein to a subject in need thereof, thereby reducing allogeneic RBC transfusions.

[0057] In one embodiment, the method further includes obtaining genotypic information to identify the HLA genotype in the subject, for example, the HLA-DRB1*09 genotype, and identifying that the presence of the HLA genotype indicates that the subject has or is at risk of having increased immunogenicity to EPO therapy. In one embodiment, the EPO molecule is administered in response to the acquisition of genotypic information.

[0058] In one embodiment, the subject possesses or has been determined to possess the HLA-DRB1*09 allele. In one embodiment, the subject has chronic kidney disease, HIV infection, or cancer. In one embodiment, the subject has received or has received zidovudine. In one embodiment, the subject has received or has received chemotherapy (e.g., myelosuppressive chemotherapy), surgery, or allogeneic RBC transfusion. In one embodiment, the subject possesses or has been determined to possess anti-EPO antibodies. In one embodiment, the subject has been administered a different recombinant human EPO (rHuEPO), for example, an EPO containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, administration of a different rHuEPO is discontinued or terminated.

[0059] In one embodiment, the disclosure is a method for evaluating a subject, comprising obtaining genotypic information that identifies an HLA genotype, for example, an HLA-DRB1*09 genotype, in the subject, and identifying that the presence of the HLA genotype indicates that the subject has, or is at risk of having, increased immunogenicity to a treatment containing an EPO molecule.

[0060] In one embodiment, the method further includes classifying a subject as a candidate for treatment with the EPO molecule disclosed herein. In one embodiment, the method further includes administering an effective amount of the EPO molecule disclosed herein to the subject.

[0061] In one embodiment, the subject possesses or has been determined to possess the HLA-DRB1*09 allele. In one embodiment, the subject has chronic kidney disease, HIV infection, or cancer. In one embodiment, the subject has received or has received zidovudine. In one embodiment, the subject has received or has received chemotherapy (e.g., myelosuppressive chemotherapy), surgery, or allogeneic RBC transfusion. In one embodiment, the subject possesses or has been determined to possess anti-EPO antibodies. In one embodiment, the subject has been administered a different recombinant human EPO (rHuEPO), for example, an EPO containing the amino acid sequence of SEQ ID NO: 1. In one embodiment, administration of a different rHuEPO is discontinued or terminated.

[0062] In one embodiment, the present disclosure features an EPO molecule described herein for use as a pharmaceutical.

[0063] In one embodiment, the present disclosure features an EPO molecule described herein for use in treating a disorder of a subject (e.g., a subject described herein) in accordance with the methods described herein.

[0064] In one embodiment, the present disclosure features an EPO molecule described herein for use in reducing an immunogenic response in a subject (e.g., a subject described herein) according to the method described herein.

[0065] In one embodiment, the present disclosure features an EPO molecule described herein for use in the treatment or prevention of pure red cell aplasia (PRCA) in a subject (e.g., a subject described herein) according to the method described herein.

[0066] In one embodiment, the present disclosure features an EPO molecule described herein for use in reducing allogeneic red blood cell (RBC) transfusion in a subject (e.g., a subject described herein) according to the method described herein.

[0067] In one embodiment, the present disclosure features the use of the EPO molecule described herein in the manufacture of a pharmaceutical product for treating a disorder of a subject (e.g., a subject described herein) according to the method described herein.

[0068] In one embodiment, the present disclosure features the use of the EPO molecule described herein in the manufacture of a pharmaceutical product for reducing an immunogenic response in a subject (e.g., a subject described herein) according to the method described herein.

[0069] In one embodiment, the present disclosure features the use of the EPO molecule described herein in the manufacture of a pharmacopoeia for the treatment or prevention of pure pure red cell aplasia (PRCA) of a subject (e.g., a subject described herein) according to the method described herein.

[0070] In one embodiment, the present disclosure features the use of the EPO molecule described herein in the manufacture of a drug for reducing allogeneic red blood cell (RBC) transfusion in a subject (e.g., a subject described herein) according to the method described herein.

[0071] Enumerated embodiments 1. An EPO molecule containing a mutation at the position disclosed herein.

[0072] 2. The EPO molecule of Embodiment 1, comprising a mutation at a position corresponding to any of positions 12 to 152 of Sequence ID No. 1.

[0073] 3. An EPO molecule of Embodiment 1 or 2, comprising a mutation at a position corresponding to any of the positions 74-82, 102-116, or 142-153 of SEQ ID NO: 1.

[0074] 4. An EPO molecule of any of Embodiments 1 to 3, comprising a mutation at a position corresponding to any of positions 74-82 or 102-116 of SEQ ID NO: 1.

[0075] 5. An EPO molecule according to any of Embodiments 1 to 4, comprising a mutation at a position corresponding to either position 74-82 or position 142-153 of Sequence ID No. 1.

[0076] 6. An EPO molecule according to any of Embodiments 1 to 5, comprising a mutation at a position corresponding to either position 102-116 or position 142-153 of Sequence ID No. 1.

[0077] 7. An EPO molecule of any of Embodiments 1 to 6, comprising a mutation at a position corresponding to any of positions 74 to 82 of Sequence ID No. 1.

[0078] 8. An EPO molecule according to any of Embodiments 1 to 7, comprising a mutation at a position corresponding to any of positions 102 to 116 of Sequence ID No. 1.

[0079] 9. An EPO molecule of any of Embodiments 1 to 8, comprising a mutation at a position corresponding to any of positions 102 to 110 of Sequence ID No. 1.

[0080] 10. An EPO molecule according to any of Embodiments 1 to 9, comprising a mutation at a position corresponding to any of positions 108 to 116 of Sequence ID No. 1.

[0081] 11. An EPO molecule of any of Embodiments 1 to 10, comprising a mutation at a position corresponding to any of positions 142 to 153 of Sequence ID No. 1.

[0082] 12. An EPO molecule according to any of Embodiments 1 to 11, comprising a mutation at a position corresponding to any of positions 142 to 150 of Sequence ID No. 1.

[0083] 13. An EPO molecule according to any of Embodiments 1 to 12, comprising a mutation at a position corresponding to any of positions 145 to 153 of Sequence ID No. 1.

[0084] 14. An EPO molecule of any of Embodiments 1 to 13, comprising a mutation at a position corresponding to any of positions 74, 75, 76, 77, 79, 80, 81, 82, 102, 105, 106, 109, 111, 112, 113, 114, 115, 116, 142, 145, 146, 148, 149, 152, or 153 of SEQ ID NO: 1.

[0085] 15. An EPO molecule of any of Embodiments 1 to 14, comprising a mutation at a position corresponding to any of positions 12, 15, 67, 70, 74, 102, 105, 106, 109, 114, 146, 149, or 152 of SEQ ID NO: 1.

[0086] 16. An EPO molecule of any of Embodiments 1 to 15, comprising multiple mutations (e.g., multiple mutations disclosed herein) at multiple positions (e.g., multiple positions disclosed herein).

[0087] 17. An EPO molecule of Embodiment 16, further comprising a second mutation at the second position disclosed herein.

[0088] 18. The EPO molecule of Embodiment 17, further comprising a third mutation at the third position disclosed herein.

[0089] 19. The EPO molecule of Embodiment 18, further comprising a fourth mutation at the fourth position disclosed herein.

[0090] 20. The EPO molecule of Embodiment 19, further comprising a fifth mutation at the fifth position disclosed herein.

[0091] 21. An EPO molecule according to any of Embodiments 1 to 20, comprising a mutation at the position corresponding to position 12 of Sequence ID No. 1.

[0092] 22. The EPO molecule of Embodiment 21, wherein the mutation is an L12A substitution.

[0093] 23. The EPO molecule of Embodiment 21, wherein the mutation is an L12I substitution.

[0094] 24. An EPO molecule according to any of Embodiments 1 to 23, comprising a mutation at the position corresponding to position 15 of Sequence ID No. 1.

[0095] 25. The EPO molecule of Embodiment 24, wherein the mutation is a Y15I substitution.

[0096] 26. The EPO molecule of Embodiment 24, wherein the mutation is a Y15W substitution.

[0097] 27. An EPO molecule according to any of Embodiments 1 to 26, comprising a mutation at the position corresponding to position 67 of Sequence ID No. 1.

[0098] 28. The EPO molecule of Embodiment 27, wherein the mutation is an L67D substitution.

[0099] 29. The EPO molecule of Embodiment 27, wherein the mutation is an L67N substitution.

[0100] 30. The EPO molecule of Embodiment 27, wherein the mutation is an L67V substitution.

[0101] 31. An EPO molecule of any of Embodiments 1 to 30, comprising a mutation at the position corresponding to position 70 of Sequence ID No. 1.

[0102] 32. An EPO molecule of embodiment 31, wherein the mutation is an L70V substitution.

[0103] 33. An EPO molecule according to any of Embodiments 1 to 32, comprising a mutation at the position corresponding to position 74 of Sequence ID No. 1.

[0104] 34. The EPO molecule of Embodiment 33, wherein the mutation is a V74D substitution.

[0105] 35. The EPO molecule of Embodiment 33, wherein the mutation is a V74L substitution.

[0106] 36. The EPO molecule of Embodiment 33, wherein the mutation is a V74N substitution.

[0107] 37. An EPO molecule according to any of Embodiments 1 to 36, comprising a mutation at the position corresponding to position 102 of Sequence ID No. 1.

[0108] 38. The EPO molecule of Embodiment 37, wherein the mutation is an L102D substitution.

[0109] 39. The EPO molecule of Embodiment 37, wherein the mutation is an L102N substitution.

[0110] 40. The EPO molecule of Embodiment 37, wherein the mutation is an L102I substitution.

[0111] 41. The EPO molecule of Embodiment 37, wherein the mutation is an L102T substitution.

[0112] 42. The EPO molecule of Embodiment 37, wherein the mutation is an L102V substitution.

[0113] 43. An EPO molecule according to any of Embodiments 1 to 42, comprising a mutation at the position corresponding to position 105 of Sequence ID No. 1.

[0114] 44. The EPO molecule of Embodiment 43, wherein the mutation is an L105F substitution.

[0115] 45. An EPO molecule of Embodiment 43, wherein the mutation is an L105S substitution.

[0116] 46. ​​An EPO molecule according to any of Embodiments 1 to 45, comprising a mutation at the position corresponding to position 106 of Sequence ID No. 1.

[0117] 47. An EPO molecule of Embodiment 46, wherein the mutation is a T106A substitution.

[0118] 48. An EPO molecule of Embodiment 46, wherein the mutation is a T106G substitution.

[0119] 49. An EPO molecule of embodiment 46, wherein the mutation is a T106H substitution.

[0120] 50. An EPO molecule according to any of Embodiments 1 to 49, comprising a mutation at the position corresponding to position 109 of Sequence ID No. 1.

[0121] 51. An EPO molecule of Embodiment 50, wherein the mutation is an L109A substitution.

[0122] 52. An EPO molecule of Embodiment 50, wherein the mutation is an L109C substitution.

[0123] 53. An EPO molecule of Embodiment 50, wherein the mutation is an L109W substitution.

[0124] 54. An EPO molecule of any of Embodiments 1 to 53, comprising a mutation at the position corresponding to position 114 of Sequence ID No. 1.

[0125] 55. An EPO molecule of Embodiment 54, wherein the mutation is an A114C substitution.

[0126] 56. An EPO molecule according to any of Embodiments 1 to 55, comprising a mutation at the position corresponding to position 146 of Sequence ID No. 1.

[0127] 57. An EPO molecule of embodiment 56, wherein the mutation is an S146N substitution.

[0128] 58. An EPO molecule according to any of Embodiments 1 to 57, comprising a mutation at the position corresponding to position 149 of Sequence ID No. 1.

[0129] 59. The EPO molecule of Embodiment 58, wherein the mutation is an L149V substitution.

[0130] 60. The EPO molecule of Embodiment 58, wherein the mutation is an L149W substitution.

[0131] 61. An EPO molecule of any of Embodiments 1 to 60, comprising a mutation at the position corresponding to position 152 of Sequence ID No. 1.

[0132] 62. An EPO molecule of Embodiment 61, wherein the mutation is a K152Q substitution.

[0133] 63. An EPO molecule according to any of Embodiments 1 to 62, comprising mutations at positions corresponding to positions 67 and 102 of Sequence ID No. 1.

[0134] 64. An EPO molecule of Embodiment 63, wherein the mutations are L67V and L102V substitutions.

[0135] An EPO molecule according to any of Embodiments 1 to 64, comprising mutations at positions corresponding to 65, 70, 74, and 102.

[0136] 66. An EPO molecule of Embodiment 65, wherein the mutations are L70V, V74L, and L102I substitutions.

[0137] An EPO molecule according to any of Embodiments 1 to 66, comprising mutations at positions corresponding to 67, 67, 74, and 102.

[0138] 68. An EPO molecule of Embodiment 67, wherein the mutations are L67N, V74N, and L102D substitutions.

[0139] 69. An EPO molecule of Embodiment 67, wherein the mutations are L67D, V74D, and L102N substitutions.

[0140] An EPO molecule according to any of Embodiments 1 to 69, comprising mutations at positions corresponding to 70, 12, 15, 105, and 149.

[0141] 71. An EPO molecule of Embodiment 70, wherein the mutations are L12A, Y15I, L105F, and L149W substitutions.

[0142] 72. An EPO molecule of Embodiment 70, wherein the mutations are L12I, Y15W, L105S, and L149V substitutions.

[0143] An EPO molecule according to any of Embodiments 1 to 72, comprising mutations at positions corresponding to 73, 109 and 114.

[0144] 74. The EPO molecule of Embodiment 73, wherein the mutations are L109C and A114C substitutions.

[0145] An EPO molecule according to any of Embodiments 1 to 74, comprising mutations at positions corresponding to 75.102, 105, 106, and 109.

[0146] 76. An EPO molecule of Embodiment 75, wherein the mutations are L102T, L105S, T106H, and L109W substitutions.

[0147] 77. An EPO molecule of Embodiment 75, wherein the mutations are L102T, L105S, T106G, and L109W substitutions.

[0148] An EPO molecule according to any of Embodiments 1 to 77, comprising mutations at positions corresponding to 78,146 and 152.

[0149] 79. An EPO molecule of Embodiment 78, wherein the mutations are S146N and K152Q substitutions.

[0150] 80. An EPO molecule according to any of Embodiments 1 to 79, having at least 80% homology to the amino acid sequence of Sequence ID No. 1.

[0151] 81. An EPO molecule of any of Embodiments 1 to 80 having at least 85% homology to the amino acid sequence of Sequence ID No. 1.

[0152] 82. An EPO molecule according to any of Embodiments 1 to 81, having at least 90% homology to the amino acid sequence of Sequence ID No. 1.

[0153] 83. An EPO molecule according to any of Embodiments 1 to 82, having at least 95% homology to the amino acid sequence of Sequence ID No. 1.

[0154] 84. An EPO molecule according to any of Embodiments 1 to 83, having at least 96% homology to the amino acid sequence of Sequence ID No. 1.

[0155] 85. An EPO molecule according to any of Embodiments 1 to 84, having at least 97% homology to the amino acid sequence of Sequence ID No. 1.

[0156] 86. An EPO molecule according to any of Embodiments 1 to 85, having at least 98% homology to the amino acid sequence of Sequence ID No. 1.

[0157] 87. An EPO molecule according to any of Embodiments 1 to 86, having at least 99% homology to the amino acid sequence of Sequence ID No. 1.

[0158] 88. An EPO molecule of any of Embodiments 1 to 87, which differs from the amino acid sequence of SEQ ID NO: 1 at positions 15 or less, in addition to the mutations (one or more mutations) at the positions (one or more positions) disclosed herein.

[0159] 89. An EPO molecule of any of Embodiments 1 to 88, which differs from the amino acid sequence of SEQ ID NO: 1 at positions 10 or less, in addition to the mutations (one or more mutations) at the positions (one or more positions) disclosed herein.

[0160] 90. An EPO molecule of any of Embodiments 1 to 89, which differs from the amino acid sequence of SEQ ID NO: 1 at positions 5 or less, in addition to the mutations (one or more mutations) at the positions (one or more positions) disclosed herein.

[0161] 91. An EPO molecule of any of Embodiments 1 to 90, which differs from the amino acid sequence of SEQ ID NO: 1 at positions 4 or lower, in addition to the mutations (one or more mutations) at the positions (one or more positions) disclosed herein.

[0162] 92. An EPO molecule of any of Embodiments 1 to 91, which differs from the amino acid sequence of SEQ ID NO: 1 at positions 3 or lower, in addition to the mutations (one or more mutations) at the positions (one or more positions) disclosed herein.

[0163] 93. An EPO molecule of any of Embodiments 1 to 92, which differs from the amino acid sequence of SEQ ID NO: 1 at positions 2 or less, in addition to the mutations (one or more mutations) at the positions (one or more positions) disclosed herein.

[0164] 94. An EPO molecule of any of Embodiments 1 to 93, which differs from the amino acid sequence of SEQ ID NO: 1 at one or fewer positions, in addition to the mutations (one or more mutations) at the positions (one or more positions) disclosed herein.

[0165] 95. An EPO molecule according to any of Embodiments 1 to 94, which differs from the amino acid sequence of Sequence ID No. 1 at positions 15 or lower.

[0166] 96. An EPO molecule according to any of Embodiments 1 to 95, which differs from the amino acid sequence of Sequence ID No. 1 at positions 10 or less.

[0167] 97. An EPO molecule according to any of Embodiments 1 to 96, which differs from the amino acid sequence of Sequence ID No. 1 at positions 5 or less.

[0168] 98. An EPO molecule according to any of Embodiments 1 to 97, which differs from the amino acid sequence of Sequence ID No. 1 at positions 4 or less.

[0169] 99. An EPO molecule according to any of Embodiments 1 to 98, which differs from the amino acid sequence of Sequence ID No. 1 at positions 3 or lower.

[0170] 100. An EPO molecule according to any of Embodiments 1 to 99, which differs from the amino acid sequence of Sequence ID No. 1 at positions 2 or less.

[0171] 101. An EPO molecule of any of Embodiments 1 to 100, which differs from the amino acid sequence of Sequence ID No. 1 at positions 1 or less.

[0172] 102. An EPO molecule according to any of Embodiments 1 to 101, comprising any amino acid sequence of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, or an amino acid sequence that differs therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids.

[0173] 103. An EPO molecule according to any of Embodiments 1 to 102, comprising any amino acid sequence of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35.

[0174] 104. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 3.

[0175] 105. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 5.

[0176] 106. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 7.

[0177] 107. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 9.

[0178] 108. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 11.

[0179] 109. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 13.

[0180] 110. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 15.

[0181] 111. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 17.

[0182] 112. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 19.

[0183] 113. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 21.

[0184] 114. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 23.

[0185] 115. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 25.

[0186] 116. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 27.

[0187] 117. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 29.

[0188] 118. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of SEQ ID NO: 31.

[0189] 119. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 33.

[0190] 120. An EPO molecule according to any of Embodiments 1 to 103, comprising or consisting of the amino acid sequence of Sequence ID No. 35.

[0191] 121. An EPO molecule of any of Embodiments 1 to 120 having reduced immunogenicity in a subject compared to a reference EPO molecule, e.g., an EPO molecule containing the amino acid sequence of SEQ ID NO: 1, when determined in vitro, ex vivo, or in vivo.

[0192] 122. An EPO molecule of Embodiment 121, wherein its immunogenicity is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to a reference EPO molecule.

[0193] 123. An EPO molecule according to Embodiment 121 or 122, wherein the target possesses the HLA-DRB1*09 allele (allele).

[0194] 124. An EPO molecule of any of Embodiments 1 to 123 that, for example, has the same or substantially the same biological activity as a reference EPO molecule, e.g., an EPO molecule containing the amino acid sequence of SEQ ID NO: 1, when determined in vitro, ex vivo, or in vivo.

[0195] 125. An EPO molecule of any of Embodiments 1 to 124 having biological activity that is 25%, 20%, 15%, 10%, 5%, or 2% or less lower than a reference EPO molecule, e.g., an EPO molecule containing the amino acid sequence of SEQ ID NO: 1, when determined in vitro, ex vivo, or in vivo.

[0196] 126. An EPO molecule according to either embodiment 124 or 125, whose biological activity is measured in an in vitro TF-1 proliferation assay.

[0197] 127. An EPO molecule of any of Embodiments 1 to 126 that can have more glycoforms, e.g., at least one, two, three, four, or five more glycoforms, compared to a reference EPO molecule, e.g., an EPO molecule containing the amino acid sequence of SEQ ID NO: 1.

[0198] An EPO molecule of any of Embodiments 1 to 127, which may have 128.6, 7, 8, 9, 10 or more glycoforms.

[0199] An EPO molecule of any of Embodiments 1 to 128, which may have 129.7, 8, or more glycoforms.

[0200] 130. An EPO molecule of any of Embodiments 1 to 129 having the same or substantially the same serum half-life as a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1.

[0201] 131. An EPO molecule of any of Embodiments 1 to 130 having an increased serum half-life, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, compared to a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1.

[0202] 132. An EPO molecule of any of Embodiments 1 to 131 having a reduced serum half-life, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% or less, compared to a reference EPO molecule, for example, an EPO molecule containing the amino acid sequence of SEQ ID NO: 1.

[0203] 133. An EPO molecule according to any of Embodiments 1 to 132, comprising a portion that extends the serum half-life of the EPO polypeptide.

[0204] 134. A fusion protein, which is an EPO molecule of any of Embodiments 1 to 133.

[0205] 135. An EPO molecule according to any of Embodiments 1 to 134, comprising the Fc domain of IgG.

[0206] 136. An EPO molecule of Embodiment 135, in which the Fc domain is covalently fused to the EPO polypeptide.

[0207] 137. An EPO molecule of Embodiment 136, wherein the N-terminus of the Fc domain is directly or indirectly covalently fused to the C-terminus of the EPO polypeptide.

[0208] 138. A pharmaceutical composition comprising an EPO molecule according to any of Embodiments 1 to 137 and a pharmaceutically acceptable carrier.

[0209] 139. A preparation comprising an EPO molecule according to any of Embodiments 1 to 137.

[0210] 140. Preparations of Embodiment 139 suitable for therapeutic use.

[0211] 141. A kit comprising an EPO molecule of any of Embodiments 1 to 137 and instructions for use.

[0212] 142. A nucleic acid encoding an EPO molecule according to any one of embodiments 1 to 137.

[0213] 143. Nucleic acids containing any of the nucleotide sequences of sequence numbers 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36, or nucleotide sequences that differ from them by 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides or less, or that are identical to them by at least 80%, 85%, 90%, 95%, 98%, or 99%.

[0214] 144. A nucleic acid of Embodiment 143 comprising any of the nucleotide sequences of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36.

[0215] 145. A vector comprising any nucleic acid of any of embodiments 142 to 144.

[0216] 146. A vector of Embodiment 145, comprising a promoter operably ligated to a nucleic acid.

[0217] 147. A cell containing the nucleic acid of any of embodiments 142 to 144.

[0218] 148. A method for producing an EPO molecule, comprising culturing the cells of Embodiment 147 under conditions that enable the expression of an EPO polypeptide, thereby producing an EPO molecule.

[0219] 149. A method for treating a disorder in a subject, comprising administering an effective amount of an EPO molecule of any of embodiments 1 to 137 to the subject, thereby treating the disorder.

[0220] 150. The method of Embodiment 149, wherein the failure is an EPO-related failure, e.g., EPO deficiency or abnormality.

[0221] 151. The method of Embodiment 150, wherein the disorder is anemia.

[0222] 152. The method of Embodiment 151, wherein the anemia is related to or caused by chronic kidney disease (e.g., chronic renal failure), zidovudine treatment, chemotherapy, or surgery.

[0223] 153. A method for reducing an immunogenic response in a subject, comprising administering an effective amount of an EPO molecule of any of Embodiments 1 to 137 to a subject in need thereof, thereby reducing the immunogenic response.

[0224] 154. A method for treating or preventing pure red cell aplasia (PRCA) in a subject, comprising administering an effective amount of an EPO molecule of any of embodiments 1 to 137 to a subject in need thereof, thereby treating or preventing PRCA.

[0225] 155. A method for reducing allogeneic red blood cell (RBC) transfusions in a subject, comprising administering an effective amount of an EPO molecule of any of Embodiments 1 to 137 to a subject in need thereof, thereby reducing allogeneic RBC transfusions.

[0226] 156. Any method of Embodiments 148 to 155, further comprising obtaining genotype information or sequences that identify an HLA genotype in a subject, for example, the HLA-DRB1*09 genotype, and identifying that the presence of the HLA genotype indicates that the subject has or is at risk of having increased immunogenicity to EPO therapy.

[0227] 157. The method of Embodiment 156, wherein the EPO molecule is administered in response to the acquisition of genotype information.

[0228] 158. A method for evaluating a subject, comprising obtaining genotype information to identify an HLA genotype in the subject, for example, an HLA-DRB1*09 genotype, and identifying that the presence of the HLA genotype indicates that the subject has or is at risk of having increased immunogenicity to a treatment containing an EPO molecule.

[0229] 159. The method of Embodiment 158, further comprising classifying subjects as candidates for treatment with the EPO molecules disclosed herein.

[0230] 160. The method of Embodiment 158 ​​or 159, further comprising administering an effective amount of the EPO molecule disclosed herein to the target.

[0231] 161. Any method of Embodiments 148 to 160, wherein the subject possesses or is determined to possess the HLA-DRB1*09 allele (allele).

[0232] 162. Any method of Embodiments 148 to 161, wherein the subject has chronic kidney disease, HIV infection, or cancer.

[0233] 163. A method according to any of Embodiments 148 to 162, wherein the subject receives or has received zidovudine.

[0234] 164. Any method of Embodiments 148 to 163, wherein the subject undergoes or has undergone chemotherapy (e.g., myelosuppressive chemotherapy), surgery, or allogeneic RBC transfusion.

[0235] 165. Any method of Embodiments 148 to 164, wherein the subject has or has been determined to have an anti-EPO antibody.

[0236] 166. Any method of Embodiments 148 to 165, wherein the subject has previously been administered a different recombinant human EPO (rHuEPO), for example, an EPO containing the amino acid sequence of SEQ ID NO: 1.

[0237] 167. The method of Embodiment 166 for discontinuing or terminating the administration of different rHuEPO. [Brief explanation of the drawing]

[0238] [Figure 1A]Figure 1A is a diagram of the amino acid sequence of EPO, showing the predicted contact points of the EPO receptor (EPO-R) (bold); the binding to the HLA-DRB1*09-DQB1*03:09 allele (shaded), the recognition by the neutralizing antibody (underlined); and exemplary sites to consider for amino acid modifications (asterisked above). Figure 1A discloses Sequence ID No. 46. [Figure 1B] Figure 1B shows the structure of the EPO-R binding interface, which exhibits a network of interacting hydrophobic amino acids including exemplary allele binding sites. [Figure 2] Figures 2A and 2B show images of exemplary EPO polypeptides separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) after Coomassie blue staining (Figure 2A) and Western immunoblotting (Figure 2B). [Figure 3] Figure 3 shows images of isoelectric focusing (IEF) gel separation of exemplary EPO polypeptides, indicating the number of each isoform. [Figure 4] Figure 4 shows the logarithmic dose-response curve illustrating the in vitro biological activity of exemplary EPO polypeptides in TF-1 cells. [Figure 5] Figures 5A–5C are bar graphs showing the ex vivo immunogenicity of exemplary EPO polypeptides as determined by the measurement of interferon-gamma (IFN-γ) release using ELISA, providing percentages of relative response (Figure 5A), with asterisks indicating statistical significance by t-test (*p≦0.05, **p≦0.01, ***p≦0.001, ****p≦0.0001). IFN-γ levels in HLA-DRB1*09 positive volunteers (Figure 5B); IFN-γ levels in HLA-DRB1*09 negative volunteers (Figure 5C). Bar graphs are shown as mean ± standard error. [Modes for carrying out the invention]

[0239] Recombinant human erythropoietin (rHuEPO) can be used as a biopharmaceutical administered to subjects with low levels of hemoglobin, such as those with chronic kidney disease, cancer, HIV infection, or anemia. However, some subjects who are repeatedly administered rHuEPO may develop an immune response to rHuEPO and the formation of anti-rHuEPO neutralizing antibodies, which can lead to the development of pure red cell aplasia (PRCA). While we do not wish to be bound by theory, in one embodiment, the immunogenic response to EPO is thought to be triggered by T cells that recognize EPO epitopes bound to major histocompatibility complex (MHC) molecules presented on the cell surface of antigen-presenting cells (APCs). In one embodiment, there is thought to be a correlation between the expression of anti-rHuEPO-associated PRCA and the HLA-DRB1*09 gene, which is incorporated into some populations, such as the Thai population. For example, screening for HLA-DRB1*09 in volunteers living in Bangkok, Thailand, found that 22% of volunteers had HLA-DRB1*09, confirming the high frequency of this particular HLA in Thailand.

[0240] This disclosure is based, at least in part, on the discovery that the immunogenicity of an EPO polypeptide can be reduced without disrupting the structural integrity or biological activity of the EPO polypeptide by modifying its amino acid sequence. Modified EPO polypeptides or EPO variants with reduced immunogenicity are disclosed herein. Advantageously, the EPO polypeptides described herein can mimic one or more biological functions of natural EPO, for example, by supplementing or substituting endogenous EPO in a subject and / or treating or preventing anemia or EPO-related disorders (e.g., EPO deficiency-related disorders) in a subject, without producing the immune responses that may occur with other forms of recombinant human erythropoietin (rHuEPO). While not wishing to be bound by theory, in one embodiment, the EPO polypeptides described herein could be used in subjects at high risk of immunogenicity to rHuEPO, such as rHuEPO-dependent subjects and / or subjects expressing specific class II MHC alleles (alleles) such as HLA-DRB1*09. For example, the EPO polypeptide described herein can be used to treat patients in populations at high risk of immunogenicity to rHuEPO, such as the Thai population.

[0241] Methods for screening EPO polypeptides (e.g., computationally and / or experimentally) for the identification and characterization of immunogenic hotspots in EPO polypeptides recognized by MHC alleles (e.g., HLA-DRB1*09) are also described herein. These methods can be further used to predict mutants having one or more (e.g., 2, 3, 4, or more) mutations that reduce affinity to an allele. Furthermore, nucleic acid molecules encoding EPO polypeptides, expression vectors, host cells, compositions (e.g., pharmaceutical compositions), kits, containers, devices, and methods for producing EPO polypeptides are also provided herein. The EPO polypeptides and pharmaceutical compositions disclosed herein can be used alone or in combination with other agents or modes of therapy to treat and / or prevent disorders and conditions, such as anemia or conditions associated with EPO deficiency, such as pure red cell aplasia (PRCA).

[0242] definition As used herein, the articles "a" and "an" refer to one or more grammatical objects of the article (e.g., up to one).

[0243] The term "or" is used herein to mean and is interchangeable with the term "and / or" unless otherwise explicitly indicated in the context.

[0244] "About" and "approximately" generally refer to an acceptable degree of error in the measured quantity, taking into account the nature or precision of the measurement. Exemplary degrees of error are within 20% (%) of a given value or range of values, typically within 10%, and more typically within 5% (e.g., within 4%, 3%, 2%, or 1%).

[0245] As used herein, “to obtain” or “to acquire” means to acquire ownership of a physical entity or value, such as a numerical value, by “directly obtaining” or “indirectly obtaining” the physical entity or value. “Directly obtaining” means to carry out a process to obtain the physical entity or value (e.g., performing a synthesis or analytical method). “Indirectly obtaining” means to receive the physical entity or value from another entity or source (e.g., a third-party laboratory that directly obtained the physical entity or value). Directly obtaining a physical entity involves carrying out a process that includes a physical change of a physical substance, such as a starting material. Exemplary changes include making a physical entity from two or more starting materials, shearing or fragmenting a substance, separating or purifying a substance, combining two or more distinct entities into a mixture, and carrying out a chemical reaction that includes breaking or forming covalent or non-covalent bonds. Obtaining a value directly includes performing a process that involves a physical change of a sample or another substance, for example, performing an analytical process that involves a physical change of a substance, such as a sample, analyte, or reagent (which may also be referred to herein as “physical analysis”), performing an analytical method, for example, a method that includes one or more of separating or purifying a substance, such as an analyte, or a fragment or other derivative thereof from another substance; combining an analyte, or a fragment or other derivative thereof, with another substance, such as a buffer, solvent, or reactant; or altering the structure of an analyte, or a fragment or other derivative thereof, for example, by breaking or forming a covalent or non-covalent bond between a first atom and a second atom of the analyte; or altering the structure of a reagent, or a fragment or other derivative thereof, for example, by breaking or forming a covalent or non-covalent bond between a first atom and a second atom of the reagent.

[0246] "To obtain a sequence," as used herein, means to acquire ownership of a nucleotide or amino acid sequence by "directly obtaining" or "indirectly obtaining" the sequence. "To obtain a sequence directly" means to perform a process to obtain a sequence (e.g., performing a synthesis or analytical method), such as performing a sequencing method (e.g., a next-generation sequencing (NGS) method). "To obtain a sequence indirectly" means to receive information or knowledge of a sequence, or a sequence, from another entity or source (e.g., a third-party laboratory that directly obtained the sequence). The sequence obtained does not have to be a complete sequence; for example, sequencing at least one nucleotide, or obtaining information or knowledge to identify a fusion molecule disclosed herein as being present in a subject, constitutes obtaining a sequence.

[0247] Directly obtaining a sequence involves performing a process that includes physical alterations to a physical substance, such as a starting material, such as a tissue sample, such as a biopsy, or a nucleic acid (e.g., DNA or RNA) sample. Exemplary alterations include producing a physical entity from two or more starting materials, shearing or fragmenting a substance (e.g., a genomic DNA fragment), separating or purifying a substance (e.g., isolating a nucleic acid sample from a tissue), combining two or more distinct entities into a mixture, and performing chemical reactions that include breaking or forming covalent or non-covalent bonds.

[0248] The compositions and methods disclosed herein include polypeptides and nucleic acids having a specified sequence, or a sequence substantially identical or similar thereto, for example, having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or more of the specified sequence.

[0249] In relation to amino acid sequences, the term “substantially identical” is used herein to mean a first amino acid sequence that is either a) identical to the second amino acid sequence, or b) contains a sufficient or minimum number of amino acid residues that are conservative substitutions of aligned amino acid residues in the second amino acid sequence, such that the first and second amino acid sequences may have a common structural domain and / or common functional activity. For example, an amino acid sequence containing a common structural domain having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity with respect to a reference sequence, e.g., a sequence provided herein.

[0250] In relation to nucleotide sequences, the term “substantially identical” is used herein to refer to a first nucleic acid sequence containing a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in the second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or common functional polypeptide activity. For example, a nucleotide sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity with a reference sequence, e.g., a sequence provided herein.

[0251] The term "functional variant" refers to a polypeptide that has substantially the same amino acid sequence as a naturally occurring sequence, or is encoded by substantially the same nucleotide sequence, and can possess one or more of the activities of a naturally occurring sequence.

[0252] The calculation of homology or sequence identity between sequences (these terms are used interchangeably herein) is performed as follows:

[0253] To determine the percentage of identity between two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (for example, gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, and non-homologous sequences can be ignored for comparison purposes). In a typical embodiment, the length of the reference sequence aligned for comparison purposes is at least 30% of the length of the reference sequence, e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, or 100%. Then, amino acid residues or nucleotides at the corresponding amino acid or nucleotide positions are compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position.

[0254] The percentage of identity between two arrays is a function of the number of identical positions shared by the arrays, taking into account the number of gaps that need to be introduced for optimal alignment of the two arrays and the length of each gap.

[0255] The comparison of sequences and the determination of the percentage of identity between two sequences can be achieved using mathematical algorithms. In one embodiment, the percentage of identity between two amino acid or nucleotide sequences is determined using lustal Omega (Sievers et al. Mol Syst Biol. 2011;7:539). In one embodiment, the percentage of identity between two amino acid or nucleotide sequences is determined using Kalign2 (Lassmann et al. Nucleic Acids Res. 2009;37(3):858-65;Lassmann and Sonnhammer BMC Bioinformatics. 2005;6:298). In one embodiment, the percentage of identity between two amino acid or nucleotide sequences is determined using MAFFT (Katoh and Standley Mol Biol Evol. 2013;30(4):772-80). In one embodiment, the percentage of identity between two amino acid or nucleotide sequences is determined using MUSCLE (Edgar Nucleic Acids Res. 2004; 32(5): 1792-7; Edgar BMC Bioinformatics. 2004; 5: 113). In another embodiment, the percentage of identity between two amino acid or nucleotide sequences is determined using MView (Brown et al. Bioinformatics. 1998; 14(4): 380-1). Other methods for determining the percentage of identity between two sequences are also described, for example, Li et al. Nucleic Acids Res. 2015; 43(W1): W580-4; McWilliam et al. Nucleic Acids Res. 2013; 41(Web Server issue): W597-600.

[0256] In one embodiment, the percentage of identity between two amino acid sequences is determined using either a Blossum 62 matrix or a PAM 250 matrix, with gap weightings of 16, 14, 12, 10, 8, 6, or 4, and length weightings of 1, 2, 3, 4, 5, or 6, using the Needleman and Wunsch (J Mol Biol. 1970;48(3):443-53) algorithm, which is incorporated into the GAP program of the GCG software package (available at www.gcg.com). In one embodiment, the percentage of identity between two nucleotide sequences is determined using NWSgapdna, with gap weightings of 40, 50, 60, 70, or 80, and length weightings of 1, 2, 3, 4, 5, or 6, using the CMP matrix and a gap weighting of 40, 50, 60, 70, or 80, and length weightings of 1, 2, 3, 4, 5, or 6. One appropriate set of parameters (and the one that should be used unless otherwise specified) is a Blossum 62 scoring matrix with a gap penalty of 12, a gap expansion penalty of 4, and a frameshift gap penalty of 5.

[0257] The percentage of identity between two amino acid or nucleotide sequences can be determined using the algorithm of Meyers and Miller (Comput.Appl.Biosci.1988;4(1):11-7), which is incorporated into the ALIGN program (version 2.0), using the PAM120 weighted residue table, gap length penalty 12, and gap penalty 4.

[0258] The nucleic acid and protein sequences described herein can be used as "query sequences" to perform searches against public databases, for example, to identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) described in Altschul, et al. 1990; J. Mol. Biol. 215:403-10. A BLAST nucleotide search can be performed using the NBLAST program with a score of 100 and a word length of 12 to obtain nucleotide sequences homologous to the nucleic acids described herein. A BLAST protein search can be performed using the XBLAST program with a score of 50 and a word length of 3 to obtain amino acid sequences homologous to the protein molecules described herein. To obtain gapped alignments for comparison purposes, gap BLAST, as described in Altschul et al., Nucleic Acids Res. 1997; 25:3389-3402, can be used. When using the BLAST and gap BLAST programs, the default parameters of each program (e.g., XBLAST and NBLAST) can be used. Please refer to www.ncbi.nlm.nih.gov.

[0259] It is understood that the molecules described herein may have additional conserved or non-essential amino acid substitutions that do not substantially affect their function.

[0260] As used herein, the term "allele" refers to an alternative form of a gene. For example, the alleles described herein may be naturally occurring sequence variants of human genes. In one embodiment, the human gene is a human leukocyte antigen (HLA) gene, e.g., HLA-A, -B, -DR, or -DQ alleles, e.g., DRA, DRB1, DRB3 / 4 / 5, DQA-I, DQB1, DPA-I, or DPB1 allele, e.g., HLA-DRB1*09.

[0261] The term "amino acid" is intended to encompass all molecules that can be included in polymers of naturally occurring amino acids, whether natural or synthetic, including both amino- and acid-functional properties. Exemplary amino acids include naturally occurring amino acids; their analogues, derivatives, and homologues; amino acid analogues with variant side chains; and all of the aforementioned stereoisomers. As used herein, the term "amino acid" includes both D- or L-optical isomers and peptide mimetic forms.

[0262] The term "antigen-presenting cell" or "APC" refers to immune system cells such as accessory cells (e.g., B cells, dendritic cells, etc.) that present antigens on their surface that have formed complexes with the major histocompatibility complex (MHC), such as the MHC-II epitope complex. T cells can recognize these complexes using their T cell receptors (TCRs). APCs internalize the antigens and process them (e.g., into peptides (epitopes)) and present them to T cells.

[0263] A "conservative amino acid substitution" is a substitution of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains are defined in the art. These families include amino acids having basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), non-charged side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0264] As used herein, the term “immunogenicity” refers to the ability of a molecule (e.g., an antigen, epitope, or protein, e.g., EPO polypeptide) to induce an immune response (e.g., humoral and / or cellular immune response) in a subject. Immune responses may include, among other things, the production of antibodies (e.g., neutralizing or non-neutralizing antibodies), the formation of immune complexes, complement activation, mast cell activation, inflammation, and / or anaphylaxis. Those skilled in the art can readily measure or determine the immunogenicity of a substance. For example, humoral immunological responses can be determined, among other things, by measuring the level of antibodies in a biological sample (e.g., blood) using Western blotting, ELISA, or similar techniques. Cell-mediated immunological responses can be determined, for example, by proliferation assays (CD4 + This can be determined using T cell assays, cytotoxic T lymphocyte assays, or immunohistochemistry.

[0265] As used herein, the term “reduced immunogenicity” refers to a reduced ability to induce an immune response compared to the immunogenicity of a reference molecule (e.g., wild-type or naturally occurring EPO polypeptide, BRP to EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). For example, a molecule (e.g., a protein, e.g., an EPO polypeptide) may have reduced immunogenicity compared to a reference molecule (e.g., wild-type EPO) if, for example, it induces fewer neutralizing or non-neutralizing antibodies, as determined by antibody titers; shows reduced binding to one or more MHC alleles; or induces fewer T cell activations or T cell activations in a reduced number of subjects.

[0266] As used herein, the term “MHC-binding epitope” refers to an epitope (e.g., a peptide) that can bind to one or more class II MHC alleles (alleles) with sufficient affinity to enable the formation of an MHC epitope-T cell receptor complex and initiate T cell activation. The MHC-binding epitopes described herein may be peptide sequences (e.g., linear peptide sequences) comprising at least about nine amino acid residues, for example, at least about 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acid residues. In one embodiment, the MHC-binding epitope is a peptide sequence comprising about nine amino acid residues.

[0267] The terms “polypeptide,” “peptide,” and “protein” (in the case of a single chain) are used interchangeably herein and refer to polymers of amino acids of any length. The polymers may be linear or branched, may contain modified amino acids, or may be interrupted by non-amino acids. The term also encompasses any other operations on modified amino acid polymers, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or conjugation with labeling components. Polypeptides can be isolated from natural sources, produced by recombinant techniques from eukaryotic or prokaryotic hosts, or are products of synthetic procedures.

[0268] The terms “nucleic acid,” “nucleic acid sequence,” “nucleotide sequence,” or “polynucleotide sequence” and “polynucleotide” are used interchangeably herein. These terms refer to polymeric forms of nucleotides of any length, either deoxyribonucleotides, ribonucleotides, or their analogues. Polynucleotides can be single-stranded or double-stranded, and if single-stranded, they can be coding or non-coding (antisense) strands. Polynucleotides may include modified nucleotides such as methylated nucleotides and nucleotide analogues. Nucleotide sequences may be interrupted by non-nucleotide components. Polynucleotides may be further modified after polymerization, such as by conjugation with labeling components. Nucleic acids may be recombinant polynucleotides, or polynucleotides of genomic, cDNA, semi-synthetic, or synthetic origin that are not naturally occurring or are linked to other polynucleotides in unnatural sequences.

[0269] As used herein, the term “isolated” refers to material that has been removed from its original or native environment (e.g., the natural environment, if it occurs naturally). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, while the same polynucleotide or polypeptide separated from some or all of its coexisting material in a natural system by human intervention is isolated. Such polynucleotides may be part of a vector, and / or such polynucleotides or polypeptides may be part of a composition, and such vectors or compositions may still be isolated in that they are not part of the environment in which they are found in nature.

[0270] As used herein, “Subject” refers to a human or an animal. Animals are typically vertebrates, e.g., primates, rodents, domestic animals, or play animals. Primates include chimpanzees, crab-eating macaques, spider monkeys, and macaques (e.g., rhesus macaques). Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic animals and play animals include cattle, horses, pigs, deer, bison, buffalo, feline species (e.g., domestic cats), canine species (e.g., dogs, foxes, wolves), avian species (e.g., chickens, emus, ostriches), and fish (e.g., trout, catfish, and salmon). In certain embodiments of this disclosure, the subject is a mammal (e.g., a primate, e.g., a human). The subject may be male or female. In certain embodiments, the subject is a mammal. Mammals may be, but are not limited to, humans, non-human primates, mice, rats, dogs, cats, horses, or cattle. In one embodiment, the term “subject” is intended to include organisms (e.g., mammals, e.g., human subjects) from which an immune response can be induced.

[0271] As used herein, the term “treat” anemia or EPO-related disorder (e.g., EPO deficiency-related disorder) (e.g., pure red cell aplasia) means that a subject (e.g., a human) having and / or experiencing symptoms of a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder), will, in one embodiment, suffer less severe symptoms and / or recover more quickly if an EPO polypeptide (e.g., the EPO polypeptide described herein) is administered, compared to if no EPO polypeptide is administered. In one embodiment, when anemia or EPO-related disorder (e.g., EPO deficiency-related disorder) is treated, hemoglobin levels or activity may increase in the treated subject compared to an equivalent untreated subject. Methods for determining hemoglobin levels are described (see, for example, Billett HH (1990) Hemoglobin and Hematocrit. (Walker HK, Hall WD, Hurst JW, editors). Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition, Chapter 151. Boston: Butterworths). Treatment can, for example, partially or completely, alleviate, improve, reduce, inhibit, or decrease the severity and / or incidence of one or more of the effects, symptoms, characteristics and / or causes of a disorder, such as anemia or EPO-related disorder (e.g., EPO deficiency-related disorder), and optionally delay its onset.

[0272] In one embodiment, treatment can partially or completely mitigate, improve, reduce, inhibit, or decrease the severity and / or incidence of immunogenicity to EPO polypeptides (e.g., recombinant human EPO or endogenous human EPO) in a subject, and optionally delay the onset. In one embodiment, when anemia or EPO-related disorder (e.g., EPO deficiency-related disorder) is treated with an EPO polypeptide (e.g., the EPO polypeptides described herein), the immune response in the subject may be reduced or eliminated compared to the immune response in a comparable subject treated with a different EPO polypeptide (e.g., rHuEPO, e.g., epoetin alpha, beta, delta, or omega). For example, a diagnostic method using an enzyme-linked immunosorbent assay (ELISA) can detect the level of T cell response attributable to a different EPO polypeptide as a measure of EPO polypeptide immunogenicity (e.g., by quantifying the level of interferon-gamma (IFN-γ) release). Other assays, such as antibody titers, can be used to monitor patient treatment or detect the presence of an immune response.

[0273] In one embodiment, treatment is the treatment of subjects who do not show specific signs of a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder), and / or subjects who show only initial signs of a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder). In one embodiment, treatment is the treatment of subjects who show one or more established signs of a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder). In one embodiment, treatment is the treatment of subjects diagnosed with a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder). In one embodiment, the disorder is an EPO-related disorder (e.g., EPO deficiency-related disorder) as described herein. In one embodiment, the disorder is pure red cell aplasia.

[0274] As used herein, the term “prevents” a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder) (e.g., pure red cell aplasia) means that if a subject (e.g., a human) is administered an EPO polypeptide (e.g., the EPO polypeptide described herein), the subject is less likely to have a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder). In one embodiment, the subject is at risk of developing a disorder, e.g., anemia or EPO-related disorder (e.g., EPO deficiency-related disorder). In one embodiment, the subject is at risk of developing pure red cell aplasia. In one embodiment, the disorder is an EPO-related disorder (e.g., EPO deficiency-related disorder) described herein. In one embodiment, the disorder is pure red cell aplasia.

[0275] "Variant erythropoietin (EPO) polypeptide," "modified EPO polypeptide," "EPO variant," "EPO mutant," and "EPO mutain" are used interchangeably herein and refer to a naturally occurring polypeptide that differs from a reference EPO polypeptide, e.g., wild-type or parental EPO polypeptide, by at least one residue (e.g., by at least one amino acid insertion, deletion, or substitution). An EPO variant is characterized by a predetermined property of the mutation that distinguishes the protein from a naturally occurring allele or interspecies variant of the EPO polypeptide sequence. EPO variants described herein may exhibit one or more biological properties (e.g., one or more biological activities) comparable to naturally occurring EPO. Furthermore, EPO variants described herein may be engineered to have one or more different biological properties (e.g., reduced immunogenicity) compared to a reference EPO polypeptide, e.g., wild-type or naturally occurring EPO. In one embodiment, an EPO variant includes insertions, deletions, and / or substitutions that can be at any position in the amino acid sequence, e.g., N-terminus, C-terminus, or internally. In one embodiment, the EPO variant includes at least one residue that differs from a reference EPO polypeptide, e.g., a wild-type or naturally occurring EPO polypeptide, e.g., a difference of at least 1, 2, 3, 4, 5, or more amino acid residues. In one embodiment, the EPO variant includes 1, 2, 3, or 4 amino acid residues that differ from a reference EPO polypeptide, e.g., a wild-type or naturally occurring EPO polypeptide. In one embodiment, the EPO variant is subjected to co-translation or post-translational modification, e.g., synthetic derivatization, glycosylation, PEGylation, cyclic substitution, cyclization, fusion to a protein or protein domain (e.g., immunoglobulin), or addition of a peptide tag or label to one or more amino acid side chains or terminals.

[0276] As used herein, the terms "erythropoietin molecule" or "EPO molecule" may refer to molecules comprising full-length EPO polypeptide or functional fragments thereof.

[0277] As used herein, the terms “variant erythropoietin (EPO) nucleic acid,” “modified EPO nucleic acid,” and “variant EPO nucleic acid” are interchangeable herein and refer to nucleic acids encoding an erythropoietin protein variant (or modified EPO polypeptide). Due to the degeneracy of the genetic code, numerous nucleic acids may encode the variant erythropoietin proteins of this disclosure by, for example, modifying the sequence of one or more codons in such a way as not altering the amino acid sequence of the corresponding variant erythropoietin protein.

[0278] As used herein, the terms “wild type,” “wild-type,” or “WT” refer to polypeptides, proteins, or nucleic acids containing naturally occurring amino acid sequences or nucleotide sequences, including allele variations such as unmodified or manipulated amino acid sequences or nucleotide sequences. For example, a wild-type EPO polypeptide may refer to any EPO polypeptide containing a naturally occurring amino acid sequence (including isolated EPO polypeptides, recombinant EPO polypeptides, or synthetic EPO polypeptides containing a naturally occurring amino acid sequence).

[0279] Scope: Throughout this disclosure, various embodiments can be presented in scope form. It should be understood that scope form descriptions are for convenience and brevity only and should not be interpreted as inflexible limitations on the scope of this disclosure. Therefore, scope descriptions should be considered to specifically disclose all possible sub-scopes and the individual numbers within those scopes. For example, a scope description such as 1-6 should be considered to specifically disclose sub-scopes such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, and the individual numbers within those scopes, e.g., 1, 2, 3.7, 3, 4, 5, 5.6, and 6. As another example, a scope such as 95-99% identity includes those having 95%, 96%, 97%, 98%, or 99% identity, and includes sub-scopes such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98%, and 98-99% identity. This applies regardless of the width of the scope.

[0280] Various embodiments of the compositions and methods of this specification are described in further detail below. Further definitions are provided throughout this specification.

[0281] Erythropoietin (EPO) Human erythropoietin (EPO) Erythropoietin (EPO) is a glycoprotein hormone produced in the kidney and plays an essential role in the production and maturation of red blood cells (RBCs). The mature amino acid sequence of human EPO typically contains 165 amino acid residues and has a relative molecular weight of approximately 30,600 daltons. The EPO structure has a four-helix bundle topology containing helices A, B, C, and D. Glycosylation of EPO occurs during post-translational modification and involves the addition of three N-linked carbohydrate chains and one O-linked carbohydrate chain, along with an increase in the original molecular weight of approximately 40%. Glycosylation of EPO is known to affect protein stability, solubility, and biological activity.

[0282] The amino acid and nucleotide sequences of human EPO are known in the art. An exemplary amino acid sequence of wild-type human EPO is provided below.

Number

[0283] The numbering of EPO amino acid positions used herein is typically based on the amino acid sequence of SEQ ID NO: 1.

[0284] Recombinant human erythropoietin (rHuEPO) Recombinant human erythropoietin (rHuEPO or rhEPO), sometimes known as an erythropoiesis agent (ESA), can be a biopharmaceutical containing an engineered form of erythropoietin (EPO) that has the same or a modified amino acid sequence as human EPO. rHuEPO is commonly administered to subjects with low hemoglobin levels (anemia), for example, for an underlying disease or treatment. Exogenous EPO polypeptides such as rHuEPO have several disease areas and related uses. For example, subjects with chronic kidney disease (CKD) are commonly given rHuEPO to treat associated anemia. Other diseases commonly associated with rHuEPO treatment include HIV infection, AIDS, and cancer. Furthermore, subjects who are dependent on dialysis or receiving chemotherapy, radiation, or AIDS or HIV therapy are commonly treated with rHuEPO. Additionally, rHuEPO can be administered to subjects undergoing or who have undergone surgery or transplantation (e.g., bone marrow transplantation) to promote erythropoiesis. rHuEPO can also be used as a performance-enhancing drug, and some forms of EPO are prohibited from use in sports by the World Anti-Doping Agency. Non-exclusive examples of rHuEPO include epoetin alfa (e.g., EPOGEN®, EPOADE®, EPOPEN®, EPOXITIN®, EPREX®, ERYPRO®, ESPO®, GLOBUREN®, PROCRIT®), epoetin beta (e.g., EPOCH, EPOGIN®, ERANTIN®, ERITROGEN®, MAROGEN®, NEORECORMON®, RECORMON®), epoetin delta (e.g., DYNEPO®), and epoetin omega (e.g., EPOMAX®, HEMAX®).

[0285] As described in more detail herein, rHuEPO can elicit an immune response in some individuals due to factors related to the pharmaceutical formulation (e.g., the presence of aggregates) and / or the frequency of administration (e.g., in rHuEPO-dependent subjects), as well as particularly due to genetic factors. The immunogenicity of rHuEPO can have serious consequences, such as causing pure red cell aplasia (PRCA). Indeed, as the use of rHuEPO for the treatment of anemia in patients with chronic kidney disease (CKD) has become more widespread, some CKD patients who have previously used or are currently using rHuEPO have been reported to exhibit suspected or confirmed PRCA. For example, a 2005 report showed that four Thai patients who received rHuEPO therapy had confirmed anti-rHuEPO-related PRCA, and each subject also exhibited the HLA-DRB1*09 allele (Praditpornsilpa et al., cited above). As described herein, the DRB1*09 allele is highly prevalent among Southeast Asian countries. While we do not wish to be bound by theory, in one embodiment, disruption between the EPO epitope and the HLA-DRB1*09 molecule may reduce immunogenicity in patients with HLA-DRB1*09.

[0286] EPO variant This specification discloses variant EPO polypeptides that can be used, for example, to treat or prevent EPO-related anemia and / or disorders, such as EPO deficiency or its symptoms. For example, an EPO polypeptide may have one or more structural and / or functional properties described herein. In one embodiment, an EPO polypeptide described herein includes one or more mutations, for example, one or more mutations described herein. In one embodiment, an EPO polypeptide has lower immunogenicity compared to, for example, a reference EPO polypeptide or preparation, such as a wild-type or naturally occurring EPO polypeptide, a biological reference preparation (BRP) for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein. BRP for EPO is described, for example, in Ferguson et al. Pharmeur Bio Sci Notes. 2019; 2019:27-33; Burns et al. Pharmeur Bio Sci Notes. 2015; 2015:246-53; Behr-Gross et al. Pharmeuropa Bio. 2007 Dec; 2007(1):49-66; Behr-Gross et al. Pharmeuropa Bio. 2004 Dec; 2004(1):23-33.

[0287] In one embodiment, the EPO polypeptide described herein can be used, for example, as a substitute for conventional rHuEPO in subjects lacking endogenous EPO, for the purpose of avoiding or reducing the immunogenicity typically associated with rHuEPO and / or supplementing endogenous EPO. In one embodiment, the EPO polypeptide is administered to subjects having or at risk of having pure red cell aplasia (e.g., rHuEPO-induced PRCA). In one embodiment, the EPO polypeptide is used to treat or prevent pure red cell aplasia (e.g., rHuEPO-induced PRCA) in subjects, for example, human subjects.

[0288] Class II MHC allele binding sites In one embodiment, the EPO polypeptide described herein comprises an amino acid sequence modified to reduce immunogenicity in a subject. For example, administering the EPO polypeptide described herein to a subject can reduce (e.g., eliminate) the immune response in the subject compared to the immune response induced in an equivalent subject administered with reference rHuEPO. In one embodiment, the subject is sensitive to immunogenicity to rHuEPO and has, for example, the genetic background described herein, e.g., a subject having the HLA-DRB1*09 allele.

[0289] In one embodiment, the EPO polypeptide includes a modified binding site such that the EPO variant exhibits lower affinity for a class II MHC allele (e.g., the HLA-DRB1*09 allele). The binding site may comprise a region of approximately 9 amino acid residues. For example, the binding site predicted by the method described herein may be located at one or more positions 74–82, 102–110, 108–116, 142–150, or 145–153 of the EPO amino acid sequence. In one embodiment, the binding site comprises the amino acid sequence provided in Table 1. In one embodiment, the EPO polypeptide includes one or more mutations (e.g., 2, 3, 4, or all) in one or more of the sequence numbers 37–41 (e.g., 2, 3, 4, 5, or more). In one embodiment, the EPO polypeptide includes one or more mutations (e.g., 2, 3, 4, 5, or more) in sequence number 37. In one embodiment, the EPO polypeptide contains one or more mutations (e.g., 2, 3, 4, 5, or more) in SEQ ID NO: 38. In one embodiment, the EPO polypeptide contains one or more mutations (e.g., 2, 3, 4, 5, or more) in SEQ ID NO: 39. In one embodiment, the EPO polypeptide contains one or more mutations (e.g., 2, 3, 4, 5, or more) in SEQ ID NO: 40. In one embodiment, the EPO polypeptide contains one or more mutations (e.g., 2, 3, 4, 5, or more) in SEQ ID NO: 41. [Table 1]

[0290] EPO mutation Mutations can be introduced into the amino acid sequence of an EPO polypeptide to affect its biological properties, such as biological activity and / or immunogenicity. For example, the binding site of the EPO sequence (e.g., predicted by the methods described herein) can be modified, for example, by amino acid substitution, insertion, or deletion, to disrupt the binding between the EPO binding site and one or more class II MHC alleles (alleles), or to reduce their affinity.

[0291] In one embodiment, the EPO polypeptide contains a mutation at one or more residues on the binding side. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions selected from positions 12 to 152 of the EPO amino acid sequence. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions selected from positions 74 to 82, 102 to 116, or 142 to 153 of the EPO amino acid sequence. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions selected from positions 74 to 82. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions selected from positions 102 to 110. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions selected from positions 108 to 116. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions selected from positions 142 to 150. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions selected from positions 145 to 153.

[0292] In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions (e.g., 2, 3, 4, or more) selected from positions 74, 75, 76, 77, 78, 79, 80, 81, or 82 of the EPO amino acid sequence. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions (e.g., 2, 3, 4, or more) selected from positions 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, or 116 of the EPO amino acid sequence. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions (e.g., 2, 3, 4, or more) selected from positions 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, or 153 of the EPO amino acid sequence. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid positions (e.g., 2, 3, 4, or more) selected from positions 74, 75, 76, 77, 79, 80, 81, 82, 102, 105, 106, 109, 111, 112, 113, 114, 115, 116, 142, 145, 146, 148, 149, 152, and 153 of the EPO amino acid sequence. In one embodiment, the EPO polypeptide contains a mutation at one or more amino acid residues (e.g., 2, 3, 4, or more) selected from positions 12, 15, 67, 70, 74, 102, 105, 106, 109, 114, 146, 149, or 152.

[0293] In one embodiment, the EPO variant includes an amino acid sequence that contains substitutions at one or more positions of the human EPO amino acid sequence.

[0294] In one embodiment, the polypeptide includes a substitution at position 12, for example, L12A or L12I substitution. In one embodiment, the polypeptide includes a substitution at position 15, for example, Y15I or Y15W substitution. In one embodiment, the polypeptide includes a substitution at position 67, for example, L67D, L67N, or L67V substitution. In one embodiment, the polypeptide includes a substitution at position 70, for example, L70V substitution. In one embodiment, the polypeptide includes a substitution at position 74, for example, V74D, V74L, or V74N substitution. In one embodiment, the polypeptide includes a substitution at position 102, for example, L102D, L102I, L102N, L102T, or L102V substitution. In one embodiment, the polypeptide includes a substitution at position 105, for example, L105F or L105S substitution. In one embodiment, the polypeptide includes a substitution at position 106, for example, T106A, T106G, or T106H substitution. In one embodiment, the polypeptide includes a substitution at position 109, for example, L109A, L109C, or L109W substitution. In one embodiment, the polypeptide includes a substitution at position 114, for example, A114C substitution. In one embodiment, the polypeptide includes a substitution at position 146, for example, S146N substitution. In one embodiment, the polypeptide includes a substitution at position 149, for example, L149V or L149W substitution. In one embodiment, the polypeptide includes a substitution at position 152, for example, K152Q substitution.

[0295] In one embodiment, the polypeptide includes mutations (e.g., substitutions) at positions 67 and 102. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at positions 70, 74, and 102. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at position 102. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at positions 67, 74, and 102. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at positions 12, 15, 105, and 149. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at position 105. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at position 106. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at position 109. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at positions 109 and 114. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at positions 102, 105, 106, and 109. In one embodiment, the polypeptide includes mutations (e.g., substitutions) at positions 146 and 152.

[0296] In one embodiment, the polypeptide includes, for example, the substitution of leucine to valine at positions 67, 70, 102, and / or 149. In one embodiment, the polypeptide includes, for example, the substitution of valine to leucine at position 74. In one embodiment, the polypeptide includes, for example, the substitution of leucine to isoleucine at positions 12 and / or 102. In one embodiment, the polypeptide includes, for example, the substitution of leucine to threonine at position 102. In one embodiment, the polypeptide includes, for example, the substitution of leucine to asparagine at positions 67 and / or 102. In one embodiment, the polypeptide includes, for example, the substitution of leucine to aspartic acid at positions 67 and / or 102. In one embodiment, the polypeptide includes, for example, the substitution of leucine to alanine at positions 12 and / or 109. In one embodiment, the polypeptide includes, for example, the substitution of leucine to phenylalanine at position 105. In one embodiment, the polypeptide includes, for example, the substitution of leucine to serine at position 105. In one embodiment, the polypeptide includes, for example, a substitution of leucine for tryptophan at position 109 and / or 149. In one embodiment, the polypeptide includes, for example, a substitution of leucine for cysteine ​​at position 109. In one embodiment, the polypeptide includes, for example, a substitution of threonine for alanine at position 106. In one embodiment, the polypeptide includes, for example, a substitution of threonine for glycine at position 106. In one embodiment, the polypeptide includes, for example, a substitution of threonine for histidine at position 106. In one embodiment, the polypeptide includes, for example, a substitution of valine for asparagine at position 74. In one embodiment, the polypeptide includes, for example, a substitution of valine for aspartic acid at position 74. In one embodiment, the polypeptide includes, for example, a substitution of tyrosine for isoleucine at position 15. In one embodiment, the polypeptide includes, for example, a substitution of tyrosine for tryptophan at position 15. In one embodiment, the polypeptide includes, for example, a substitution of alanine for cysteine ​​at position 114. In one embodiment, the polypeptide includes, for example, a substitution of serine to asparagine at position 146. In another embodiment, the polypeptide includes, for example, a substitution of lysine to glutamine at position 152.

[0297] In one embodiment, the polypeptide includes L67V and L102V substitutions. In one embodiment, the polypeptide includes L70V, V74L, and L102I substitutions. In one embodiment, the polypeptide includes L102T substitutions. In one embodiment, the polypeptide includes L67N, V74N, and L102D substitutions. In one embodiment, the polypeptide includes L67D, V74D, and L102N substitutions. In one embodiment, the polypeptide includes L12A, Y15I, L105F, and L149W substitutions. In one embodiment, the polypeptide includes L12I, Y15W, L105S, and L149V substitutions. In one embodiment, the polypeptide includes L105F substitutions. In one embodiment, the polypeptide includes T106A substitutions. In one embodiment, the polypeptide includes T106G substitutions. In one embodiment, the polypeptide includes T106H substitutions. In one embodiment, the polypeptide includes L109A substitutions. In one embodiment, the polypeptide includes L109W substitutions. In one embodiment, the polypeptide includes L109C and A114C substitutions. In one embodiment, the polypeptide includes L102T, L105S, T106H and L109W substitutions. In one embodiment, the polypeptide includes L102T, L105S, T106G and L109W substitutions. In one embodiment, the polypeptide includes S146N and K152Q substitutions.

[0298] The EPO polypeptides (e.g., EPO variants) described herein may contain mutations in any one of the four helices. In one embodiment, the EPO polypeptide contains mutations within one or more of helices A, B, C, and D. In one embodiment, the EPO polypeptide contains a mutation within helix A. In one embodiment, the EPO polypeptide contains a mutation within helix B. In one embodiment, the EPO polypeptide contains a mutation within helix C. In one embodiment, the EPO polypeptide contains a mutation within helix D. In one embodiment, the EPO polypeptide contains mutations within helices B and C. In one embodiment, the mutations that an EPO variant having, for example, in vitro biological activity (e.g., EPO-1.2, EPO-3.1, EPO-3.2, EPO-3.3, or EPO-4.1 shown in Table 2) has are located within helix B and / or helix C.

[0299] While not wishing to be bound by theory, in one embodiment, amino acid positions 74, 102, 106, and 109 are thought to be epitopes of HLA-DR-B1. In one embodiment, the substitution of leucine with valine at position 70, the substitution of valine with leucine at position 74, the substitution of leucine with isoleucine at position 102 (EPO-1.2), and the substitution of leucine with alanine at position 109 (EPO-4.1) maintain the hydrophobic network of EPO. Any suitable substitution between non-polar amino acid groups can be incorporated into the EPO polypeptide, for example, between alanine, leucine, valine, and isoleucine.

[0300] In one embodiment, a single mutation (e.g., as in EPO-3.1, EPO-3.2, and EPO-3.3 in Table 2) alters the native amino acid properties. For example, a polar hydroxyl-containing amino acid such as threonine, e.g., threonine at position 106, can be substituted with a smaller and / or nonpolar amino acid such as alanine (e.g., in EPO-3.1) or glycine (e.g., in EPO-3.2). Furthermore, a heteroaromatic moiety (e.g., imidazole) can be introduced at position 106, for example, to avoid or reduce recognition by MHC II alleles (e.g., in EPO-3.3). For example, EPO polypeptides described herein, including these mutant sequences, can avoid or reduce recognition by MHC II molecules and reduce the immunogenic response in subjects having MHC II molecules that accept the EPO polypeptide.

[0301] In one embodiment, the mutation results in an EPO polypeptide with reduced HLA binding affinity compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the mutation results in an EPO polypeptide with reduced binding affinity to the HLA-DRB1*09 allele. In one embodiment, the EPO polypeptide has HLA binding affinity (e.g., HLA-DRB1*09 allele binding affinity) of approximately 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, and 80% of the HLA binding affinity of a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO polypeptide has an HLA binding affinity of less than about 90% of that of a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein), for example, about 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, or less.

[0302] EPO isoform The EPO preparations described herein may contain one or more isoforms (e.g., glycoforms) of the EPO polypeptide described herein. For example, the rHuEPO polypeptide generally has a complex glycosylation pattern and exists as several different isoforms, and fully glycosylated EPO is known to contain as many as 14 isoforms. In one embodiment, a biological reference preparation of EPO (Burns, C. et al. Pharmeus. Bio. Sci. Notes (2015) 246-253) contains six different isoforms. In one embodiment, the EPO preparation contains six or more different isoforms, e.g., 6 to 8 isoforms. While we do not wish to be bound by theory, in one embodiment, this variation in the isoform (e.g., glycoform) profile may be due to differences in the protein sequence and / or post-translational modifications of the glycan portion, for example, due to different passages of transfected cells.

[0303] In one embodiment, the EPO preparation comprises a single isoform. In one embodiment, the EPO polypeptide described herein comprises a mixture of isoforms, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more isoforms. In one embodiment, the EPO preparation comprises more isoforms compared to an EPO preparation comprising an unmodified EPO polypeptide (e.g., wild-type or naturally occurring EPO polypeptide). In one embodiment, the EPO preparation comprises 6 isoforms. In one embodiment, the EPO preparation comprises 7 isoforms. In one embodiment, the EPO preparation comprises 8 isoforms.

[0304] In one embodiment, the EPO preparation comprises a mixture of glycoforms, each glycoform having variations in the number of glycan moieties, e.g., the degree of branching of the glycan, the glycan structure (e.g., different carbohydrate or glycosidic bonds), the number of N- and O-linked glycans, and / or the number of sialic acid moieties.

[0305] The isoform (e.g., glycoform) distribution of EPO polypeptides can be determined using known techniques, such as separation using isoelectric focusing (IEF) gels. For example, an EPO preparation containing a mixture of isoforms can be separated by an IEF gel, and the number of isoforms can be determined using the number of different bands visualized on the gel. Different isoforms can be separated, for example, according to their relative acidity or basicity.

[0306] While we do not wish to be bound by theory, in one embodiment, isoform distribution may be caused by differences in minute heterogeneity of glycosylation between EPO polypeptides. Variations in the number of glycoforms of EPO polypeptides, e.g., sialic acid molecules, can significantly affect the biological activity of EPO polypeptides, including receptor binding affinity and serum clearance. Therefore, desirable characteristics can be obtained, for example, by selecting EPO polypeptides with specific glycosylation profiles to increase the biological activity of EPO polypeptides and / or decrease serum clearance. Such advantages may provide opportunities to administer EPO polypeptides at lower frequencies compared to conventional therapies (e.g., using rHuEPO). In one embodiment, an EPO polypeptide has the same serum half-life as an unmodified EPO polypeptide (e.g., wild-type or naturally occurring EPO), BRP for EPO, or a modified EPO lacking one or more (e.g., all) of the mutations described herein. In one embodiment, the EPO polypeptide has a reduced serum half-life compared to the unmodified EPO polypeptide (e.g., wild-type or naturally occurring EPO), BRP for EPO, or modified EPO lacking one or more (e.g., all) of the mutations described herein. In another embodiment, the EPO polypeptide has an increased serum half-life compared to the unmodified EPO polypeptide (e.g., wild-type or naturally occurring EPO), BRP for EPO, or modified EPO lacking one or more (e.g., all) of the mutations described herein.

[0307] Additional EPO polypeptide In one embodiment, the EPO polypeptide described herein is modified, for example, by post-translational modification. In one embodiment, the modification includes glycosylation, deglycosylation, carboxylation, hydroxylation, carbamylation, sulfation, prenylation, farnesylation, or conjugation to another molecule, such as a polymer, polypeptide, or protein (e.g., albumin, immunoglobulin, polyethylene glycol (PEG), or hydroxyalkyl starch). For example, the EPO polypeptide described herein may be conjugated (e.g., covalently bonded) to a protein or protein domain. In one embodiment, the EPO polypeptide is conjugated to albumin. In one embodiment, the EPO polypeptide is conjugated to a histidine tag (e.g., a 6×Hi tag (SEQ ID NO: 43)). In one embodiment, the EPO polypeptide is conjugated to one or more of the following: glutathione S-transferase, hemagglutinin, FLAG epitope, beta-galactosidase, luciferase, green fluorescent protein, etc.

[0308] In one embodiment, the EPO polypeptide is covalently bound to an antibody (e.g., an immunoglobulin (IgG) molecule). In another embodiment, the EPO polypeptide is covalently bound to an IgG molecule. In yet another embodiment, the EPO polypeptide is covalently bound to the Fc portion of an IgG molecule.

[0309] EPO polypeptides can be linked to other molecules (e.g., proteins, polypeptides, or polymers) by any suitable chemical means. EPO polypeptides can be linked to other molecules directly (e.g., by covalent bonds) or by linkers. For example, linking an EPO polypeptide to another molecule (e.g., a protein) may involve the use of suitable linkers such as amino acids or polypeptide linkers, including, for example, threonine, serine, proline, glycine, aspartic acid, lysine, glutamine, glutamic acid, asparagine, arginine, phenylalanine, or alanine, or combinations thereof. EPO polypeptides can be linked to other molecules (e.g., proteins) by thiol bonds (e.g., disulfide or thioether bonds) or via amine or alcohol groups. The linkage of an EPO polypeptide to another molecule may be via any suitable linking moiety, such as an aryl azide, maleimide, carbodiimide, N-hydroxysuccinimide ester, hydrazide, PFP ester, phosphine or hydroxymethylphosphine, psoralen, imide ester, pyridyl disulfide, isocyanate or vinyl sulfone.

[0310] While we do not wish to be bound by theory, it is conceivable that conjugating EPO polypeptides to other molecules (e.g., proteins such as albumin or IgG molecules) could extend the serum half-life of EPO polypeptides, facilitate purification or isolation, modify (e.g., improve) the secretion of EPO polypeptides from cells, provide epitope tags, provide detectable signals, and / or provide dimerization or multimerization.

[0311] Exemplary EPO sequence In one embodiment, the EPO polypeptide comprises an amino acid sequence adapted to achieve one or more (e.g., two, three, four, or all) of the following: (i) reduced binding affinity to a class II MHC allele (e.g., HLA-DRB1*09 allele) compared to a reference EPO polypeptide or preparation; (ii) maintenance of binding affinity to the EPO receptor; (iii) conserved structural integrity; (iv) maintained or increased serum half-life compared to a reference EPO polypeptide or preparation; and / or (v) maintained or improved biological activity compared to a reference EPO polypeptide or preparation (e.g., as measured by a cell proliferation assay or by an increase in hemoglobin in a subject). In one embodiment, the reference EPO polypeptide comprises or consists of a wild-type or naturally occurring EPO polypeptide, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein. In one embodiment, the reference EPO preparation is a BRP for EPO.

[0312] In one embodiment, the EPO polypeptide comprises an amino acid sequence provided in Table 2, or a substantially identical amino acid sequence (e.g., at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% or more identical amino acid sequence), or a functional fragment thereof. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6]

[0313] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that differs from SEQ ID NO: 1 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is identical by at least 85%, 90%, 95%, 98%, or 99%, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof. In one embodiment, the EPO polypeptide consists of the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0314] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 3, or a variant thereof that differs from SEQ ID NO: 3 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 3. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0315] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 5, or a variant thereof that differs from SEQ ID NO: 5 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 5. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0316] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 7, or a variant thereof that differs from SEQ ID NO: 7 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 7. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0317] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 9, or a variant thereof that differs from SEQ ID NO: 9 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 9. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0318] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 11, or a variant thereof that differs from SEQ ID NO: 11 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 11. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0319] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 13, or a variant thereof that differs from SEQ ID NO: 13 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 13. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0320] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 15, or a variant thereof that differs from SEQ ID NO: 15 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 15. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0321] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 17, or a variant thereof that differs from SEQ ID NO: 17 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 17. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0322] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 19, or a variant thereof that differs from SEQ ID NO: 19 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 19. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0323] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 21, or a variant thereof that differs from SEQ ID NO: 21 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 21. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0324] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 23, or a variant thereof that differs from SEQ ID NO: 23 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 23. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0325] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 25, or a variant thereof that differs from SEQ ID NO: 25 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 25. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0326] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 27, or a variant thereof that differs from SEQ ID NO: 27 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 27. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0327] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 29, or a variant thereof that differs from SEQ ID NO: 29 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 29. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0328] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 31, or a variant thereof that differs from SEQ ID NO: 31 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 31. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0329] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 33, or a variant thereof that differs from SEQ ID NO: 33 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 33. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0330] In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 35, or a variant thereof that differs from SEQ ID NO: 35 by 1, 2, 5, 10, 15, or 20 or fewer amino acids, or is at least 85%, 90%, 95%, 98%, or 99% identical thereto, or a functional fragment thereof. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 35. In one embodiment, the EPO polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or a functional fragment thereof.

[0331] In one embodiment, the EPO polypeptide is

number

[0332] Calculation Design of EPO Variant Another aspect of this disclosure features a method for designing EPO polypeptides that have lower immunogenicity compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). For example, computational studies can be performed to identify sites in the human EPO amino sequence that are predicted to bind to one or more class II MHC alleles (e.g., HLA-DRB1*09 or HLA-DRB1*09-DQB1*03:09 alleles). Using these predicted binding sites, EPO variants having one or more mutations at the binding sites can be designed to reduce (e.g., eliminate) the affinity of the EPO polypeptide variant to bind to class II MHC alleles. The computational tools can also be used, for example, to design proteins that preserve structural integrity in order to avoid a decrease in the biological activity or serum half-life of an EPO polypeptide compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, an in silico tool (e.g., NetMHCII 2.2) is used to predict sites on EPO that are favorable for binding to an MHCII allele (e.g., an HLA-DRB1*09 allele). In one embodiment, an in silico tool (e.g., NetMHCII 2.2) is used to design an EPO polypeptide sequence that results in an EPO polypeptide with reduced immunogenicity due to lower affinity for an MHCII allele (e.g., the HLA-DRB1*09 allele) compared to, for example, a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein).

[0333] Expression and Purification of EPO Variants The EPO polypeptides described herein can be produced, for example, by recombinant expression in host cells, e.g., the cells described herein, using known techniques. In one embodiment, the expression of the EPO polypeptide comprises preparing a suitable expression vector containing a sequence encoding the EPO polypeptide. The vector may be any vector described herein. For example, a pcDNA expression vector (e.g., a pcDNA 3.3 expression vector) or a suitable alternative containing a sequence encoding the EPO polypeptide can be used. Once produced and optionally purified, the expression vector can then be transfected into suitable cells. Any suitable host cells can be used, and may, among other things, be eukaryotic cells, bacterial cells, insect cells, or human cells. In one embodiment, the host cell is a human cell. In one embodiment, the host cell is a FreeStyle® 293-F cell. In one embodiment, the transfected cells are cultured, for example, according to the requirements of the cells, to produce the EPO polypeptide. The EPO polypeptide produced from the culture may then be isolated and purified, for example, by anion exchange chromatography, using known techniques.

[0334] Bioactivity of EPO variants Erythropoietin (both native and recombinant forms) can bind to and activate the EPO receptor (EPO-R), a protein found on the surface of EPO-responsive cells. While we do not wish to be constrained by theory, in one embodiment, the binding and activation of EPO-R by EPO polypeptides is thought to be involved in stimulating erythropoiesis. More specifically, EPO polypeptides can bind to the extracellular domain of EPO-R, leading to a conformational change of the receptor and triggering intracellular signaling events, namely receptor phosphorylation and activation of the JAK-STAT, RAS, and P13 kinase pathways. These events can lead to the promotion and differentiation of erythrocyte progenitor cells into erythrocytes, stimulating hemoglobin C synthesis and increasing hematocrit levels.

[0335] EPO-R can be found in erythrocytes as well as several types of non-erythrocytes, such as bone marrow cells, lymphocytes, megakaryocytes, endothelial cells, mesangial cells, cardiomyocytes, smooth muscle cells, nerve cells, prostate cells, and renal cells (for example, on their surface). Therefore, in addition to promoting erythrocyte production, EPO may affect tumors by being involved in several biological processes, including, among other important processes, such as the development of new blood vessels, as well as processes in the brain, ovaries, fallopian tubes, uterus, and testes.

[0336] In some cases, due to structural variations and identification of EPO polypeptides, EPO polypeptides can exhibit diverse biological activities in addition to the effects of different isoforms. For example, EPO polypeptide variants may have different binding affinities and / or the ability to activate EPO-R, and / or different serum half-lives, compared to unmodified EPO polypeptides (e.g., wild-type or naturally occurring EPO).

[0337] Methods for measuring the biological activity of EPO polypeptides in vitro, ex vivo, and in vivo are described. For example, the biological activity of EPO polypeptides can be determined using cell proliferation assays, for example, using cell lines that express the EPO receptor. In one embodiment, the biological activity of EPO polypeptides is determined using in vitro assays, for example, a TF-1 cell proliferation assay. The TF-1 cell line, derived from erythroleukemia patients, is stimulated upon contact with EPO and can differentiate into mature erythrocytes, thus providing a useful platform for screening the in vitro biological activity of EPO polypeptides. In particular, this cell type exhibits an EPO receptor on its surface, shows involvement in the erythrocyte lineage, possesses an intact JAK2 / STAT5 pathway, and mediates cell proliferation in response to various growth factors, including EPO (see, e.g., Broudy, VC et al. PNAS (1988) 85:6513-6517; Chretien, S. et al. Blood (1994) 83:1813-1821).

[0338] The EPO polypeptides described herein may have varying degrees of biological activity, as determined, for example, by TF-1 cell line assays. The biological activity of an EPO polypeptide can be expressed in terms of relative biological activity compared to wild-type EPO. In one embodiment, the EPO polypeptides described herein (e.g., EPO-1.2, EPO-3.1, EPO-3.2, EPO-3.3, and EPO-4.1, as shown in Table 2) exhibit the same or substantially the same in vitro biological activity as a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or modified EPO polypeptides lacking one or more (e.g., all) of the mutations described herein). While we do not wish to be bound by theory, in one embodiment, variations in biological activity on TF-1 cells may be attributed to differences in protein sequence, overall protein conformation, and / or glycosylation patterns. As described in more detail herein, the isoform pattern of EPO polypeptides can play an important role in their biological activity, potency, and / or stability (see, for example, Egrie, JCet. al. Oncology (Williston Park) (2002) 16:13-22). For example, while the in vivo activity of non-glycosylated EPO decreases, high levels of glycosylation are thought to increase the persistence of EPO and prolong its serum half-life (see, for example, Elliott, S. et al. Exp. Hematol. (2004) 32:1146-1155; Kaushik, S. et al. Protein Sci. (2011) 20:465-481; Li, H. et al. Curr Opin Biotechnol (2009) 20:678-684; Sinclair, A. et al. J. Pharm. Sci. (2005) 94:1626-1635; and Su, D., et al. Int J Hematol (2010) 91:238-244). While we do not wish to be bound by theory, in one embodiment, variations in the isoform distribution and isoform abundance within each EPO polypeptide may also explain the variations in biological activity among the EPO polypeptides described herein.

[0339] In one embodiment, the EPO polypeptide has substantially the same biological activity as a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO variant has greater biological activity (e.g., at least 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times greater) than a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO variant has lower biological activity (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% or less lower) compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO variant has substantially the same biological activity as a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein) as determined by a method described herein, such as a cell proliferation assay (e.g., a TF-1 cell proliferation assay).

[0340] In one embodiment, the EPO polypeptide variant has at least 2% of the biological activity compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein), for example, at least 3%, 4%, 5%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, 90%, 95%, 99%, or at least 99.9% of the biological activity compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO polypeptide variant has about 1-10%, about 10-20%, about 30-40%, about 40-50%, about 50-60%, about 60-70%, about 70-80%, about 80-90%, about 90-100%, about 40-45%, about 20-25%, about 2-4%, or about 5-7% of biological activity compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO polypeptide variant has greater biological activity than a reference EPO polypeptide or preparation (e.g., wild-type EPO), for example, at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 40%, 60%, 80%, 100%, 150%, 200%, 300%, 400%, or 500% or more of biological activity compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein).In one embodiment, the EPO polypeptide variant has the same or substantially the same biological activity as a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein).

[0341] In one embodiment, the EPO variant has increased stability, determined by an increased half-life in vivo or in vitro, compared, for example, to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO variant has a longer serum half-life compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein), for example, a serum half-life of about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 40%, 60%, 80%, 100%, 150%, 200%, 300%, 400%, or 500% or more compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein).

[0342] Immunogenicity of EPO polypeptide In one embodiment, the disclosure features an EPO polypeptide comprising an amino acid sequence modified to reduce (e.g., eliminate) an immune response in a subject compared to, for example, a reference EPO polypeptide or preparation (e.g., a wild-type or naturally occurring EPO polypeptide, a BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein).

[0343] The administration of exogenous proteins can stimulate the immune system of a target individual and trigger an immune response. For example, conventional rHuEPO treatment (e.g., administration of epoetin alfa) can lead to an immune response and the development of anti-rHuEPO neutralizing antibodies that can cross-react with endogenous EPO. The consequences of immunogenicity against EPO can be severe and may result in pure red cell aplasia in affected individuals. Such adverse events are associated with specific risk factors. In particular, genetic factors can significantly increase the risk of immunogenicity against rHuEPO, for example, due to the expression of specific class II MHC alleles in individuals associated with the risk of developing rHuEPO-induced pure red cell aplasia (PRCA). Furthermore, other factors, such as pharmaceutical formulations of rHuEPO, can increase the risk of immunogenicity, for example, due to protein aggregates that can trigger an immune response. Furthermore, the frequency of administration may increase the risk of forming an immune response, potentially increasing the risk of EPO-dependent subjects (e.g., those with chronic kidney disease) developing rHuEPO-induced disorders such as pure red cell aplasia.

[0344] While we do not wish to be bound by theory, in one embodiment, the immunogenicity to EPO polypeptides may be caused by the recognition of specific EPO epitopes by MHC molecules presented on the cell surface of APCs, which induce an immunogenic antibody response in the target. Certain class II MHC alleles, such as the HLA-DRB1*09 allele, are associated with a higher risk of developing rHuEPO-induced PRCA. For example, the HLA-DRB1*09 allele is frequently expressed in Thai populations at high risk of developing rHuEPO-induced pure red cell aplasia.

[0345] In one embodiment, the EPO polypeptide comprises an amino acid sequence modified to avoid or induce a low immune response in subjects having the HLA-DRB1*09 allele. In one embodiment, the EPO polypeptide has reduced HLA-binding affinity (e.g., reduced HLA-DRB1*09 allele-binding affinity) compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO polypeptide has lower immunogenicity compared to rHuEPO. In one embodiment, administration of the EPO polypeptide to a subject reduces (e.g., eliminates) the immunogenicity in the subject compared to the immunogenicity induced in an equivalent subject administered with a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the subject is susceptible to immunogenicity to rHuEPO and, for example, possesses the HLA-DRB1*09 allele.

[0346] The immunogenicity of EPO polypeptides can be determined using known methods. For example, in vitro or ex vivo assays can be used to measure, for example, the T cell response induced by EPO polypeptides. In one embodiment, an ex vivo human primary model is used. For example, blood is obtained from a subject (e.g., a subject known to be positive or negative for the HLA-DRB1*09 allele) and processed to detect precursor dendritic cells and / or T cells (e.g., CD4). + T cells can be obtained. In one embodiment, precursor dendritic cells are converted into immature dendritic cells in a culture, and then contacted with EPO polypeptide (e.g., pulsed) to obtain antigen-presenting cells. In one embodiment, dendritic cells contacted with EPO polypeptide and T cells (e.g., CD4) obtained from a blood sample can be used. +Co-culture with T cells. Dendritic cells and T cells can be co-cultured in any appropriate ratio, for example, about 1:40, 1:30, 1:20, or 1:10, respectively. In one embodiment, dendritic cells and T cells are co-cultured in a ratio of about 1:20, respectively. The T cell response can be measured by quantifying the amount of interferon-gamma (IFN-γ) released from the co-culture. In one embodiment, non-pulsed DC cells and CD4 + The level of IFN-γ from co-culture with T cells is used as a background measure of the T cell response. In one embodiment, T cells are incubated with an anti-CD3 / anti-CD28 antibody to obtain a positive control of the activated T cell response. The relative immunogenicity of the EPO polypeptide can then be determined by using a statistical comparison of the relative T cell response of the EPO polypeptide compared to a reference protein (e.g., wild-type EPO or a biorecommended product (BRP)).

[0347] In one embodiment, the EPO polypeptide induces a reduced T cell response compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, EPO induces about 90% of the response induced by a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein), for example, when measured by the magnitude of IFN-γ release. Compared to T cell responses induced by EPO polypeptides present in [the specified material], BRP for EPO, or modified EPO polypeptides lacking one or more (e.g., all) of the mutations described herein, these exhibit T cell responses of approximately 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, or less.

[0348] In one embodiment, a reference EPO polypeptide or preparation (e.g., a wild-type or naturally occurring EPO polypeptide, a BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein) induces a T cell response that is about 1 times greater than that induced by an EPO variant (e.g., an EPO variant described herein), and about 2 times, 5 times, 10 times, 100 times, 1000 times, 10,000 times, or 100,000 times greater than that induced by, for example, an EPO polypeptide.

[0349] In one embodiment, the EPO polypeptide induces a T cell response resulting in IFN-γ release of approximately 100 to 50,000 pg / mL, for example, approximately 150 to 45,000 pg / mL or approximately 200 to 40,000 pg / mL. In one embodiment, the EPO variant induces a T cell response resulting in IFN-γ release of approximately 200, 220, 240, 260, 280, 300, 400, 500, 1000, 2000, 3000, 4000, 5000, 10,000, 15,000, 20,000, 25,000, 30,000, 35,000, or 40,000 pg / mL.

[0350] In one embodiment, the EPO polypeptide has one or more amino acid mutations at positions 74, 75, 76, 77, 79, 80, 81, 82, 102, 105, 106, 109, 111, 112, 113, 114, 115, 116, 142, 145, 146, 148, 149, 152, or 153 of its amino acid sequence (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or all of them), resulting in reduced immunogenicity compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all of them) of the mutations described herein).

[0351] In one embodiment, the magnitude of immunogenicity observed with EPO polypeptides is significantly reduced in HLA-DRB1*09-positive subjects compared to HLA-DRB1*09-negative subjects. In one embodiment, reduced immunogenicity of EPO polypeptides is associated with reduced HLA-DRB1*09 binding affinity. In one embodiment, mutations in the EPO polypeptide are modified to reduce binding between the EPO epitope and the HLA-DRB1*09 paratope. In one embodiment, reduced immunogenicity of EPO polypeptides exhibits similar biological activity and / or unaffected biological function with respect to wild-type EPO polypeptides.

[0352] Animal models The EPO polypeptides described herein can be evaluated in vivo, for example, using various animal models. For example, animal models can be used to test the pharmacokinetic and / or pharmacodynamic properties of the EPO polypeptides described herein in activating EPO receptors and / or treating or preventing disorders described herein, such as anemia or EPO deficiency-related disorders, such as pure red cell aplasia. Animal models can also be used, for example, to investigate side effects, to measure the concentration of EPO polypeptides in situ, or to measure the immunogenicity of EPO polypeptides.

[0353] Exemplary animal models of EPO deficiency-related disorders described herein, which can be used to evaluate the EPO polypeptides described herein, include, but are not limited to, rodents (e.g., mice or rats, e.g., Sprague-Dawley rats). For example, a rat model of anemia associated with chronic kidney disease is described, for example, Landau, D. et al. PLoS One (2018) 13(5):e0196684, and a rat model of rHuEPO-induced pure red cell aplasia (PRCA) is described, for example, Woodburn, K. Wet. al. Exp. Hematol. (2007) 35(8):1201-1208.

[0354] Exemplary animal models of the disorders described herein are also known in the art. Exemplary types of animals that can be used to evaluate the EPO polypeptides described herein include, but are not limited to, mice, rats, rabbits, guinea pigs, dogs, and monkeys.

[0355] Nucleic acids and vectors In another embodiment, the Disclosure provides nucleic acids comprising nucleotide sequences encoding the EPO polypeptides described herein. The nucleic acids described herein may comprise nucleotide sequences encoding any one of the amino acid sequences described herein, or substantially identical sequences (for example, sequences that are at least about 85%, 90%, 95%, 99%, 99.5%, 99.9% or more identical to the sequences described herein, or sequences that differ by 3, 6, 15, 30, or 45 nucleotides or less). In one embodiment, the nucleic acid encodes an EPO polypeptide or a fragment thereof as described in Table 2. In one embodiment, the nucleic acids described herein encode EPO-1.1, EPO-1.2, EPO-1.3, EPO-1.4, EPO-1.5, EPO-2.1, EPO-2.2, EPO-2.3, EPO-3.1, EPO-3.2, EPO-3.3, EPO-4.1, EPO-4.2, EPO-4.3, EPO-5.1, EPO-5.2, or EPO-6.1, or functional fragments thereof.

[0356] In one embodiment, the nucleic acid comprises the nucleotide sequence shown in Table 2. In one embodiment, the nucleic acid comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36. In one embodiment, the nucleic acid encodes a protein comprising the amino acid sequence shown in Table 2. In one embodiment, the nucleic acid encodes a protein comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35.

[0357] The nucleic acids described herein may include deoxyribonucleotides, ribonucleotides, or analogs thereof. Nucleic acids may be single-stranded or double-stranded, and if single-stranded, they may be coding or non-coding (antisense) strands. In one embodiment, polynucleotides include modified nucleotides, such as methylated nucleotides or nucleotide analogs. The nucleotide sequences in the nucleic acids described herein may be interrupted by non-nucleotide components. In one embodiment, nucleic acids are further modified after polymerization, such as by conjugation with labeling components. Nucleic acids may be recombinant polynucleotides, or polynucleotides of genomic, cDNA, semi-synthetic, or synthetic origin. In one embodiment, the nucleic acids described herein are designed using a computational method (e.g., an in silico tool). In one embodiment, nucleic acids are generated using gene synthesis and cloned into an expression vector (e.g., a pcDNA 3.3 expression vector) for transformation in host cells.

[0358] This disclosure further features vectors comprising nucleotide sequences encoding EPO polypeptides as described herein. In one embodiment, the vector comprises nucleotide sequences encoding EPO polypeptides provided in Table 2. Vectors described herein include, but are not limited to, viruses, plasmids, cosmids, lambda phages, or yeast artificial chromosomes (YACs). In one embodiment, the vector is an expression vector, e.g., a pcDNA® expression vector, e.g., pcDNA® 3.3. A number of vector systems can be used, such as vectors utilizing DNA elements derived from animal viruses, e.g., cytomegalovirus, bovine papillomavirus, polyomavirus, adenovirus, vaccinia virus, baculovirus, retrovirus (e.g., Rous sarcoma virus, MMTV, or MOMLV), or SV40 virus. RNA elements derived from RNA viruses, such as Semryki Forest virus, Eastern Equine Encephalitis virus, and Flavivirus, can be utilized by vectors described herein.

[0359] Furthermore, markers may be introduced to enable the selection of cells that have stably incorporated the DNA into their chromosomes (i.e., transfected host cells). These markers may provide, for example, prototropy to trophic-dependent hosts, biocide resistance (e.g., antibiotics), or resistance to heavy metals such as copper. The selection marker gene may be directly ligated to the expressed DNA sequence or introduced into the same cell by co-transformation. Additional elements may also be required for optimal mRNA synthesis. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals.

[0360] An expression vector or nucleic acid sequence (e.g., a DNA sequence) containing a construct may be transfected or introduced into a suitable host cell. Various transfection techniques, such as protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene guns, lipid-based transfection, or other conventional techniques may be used. In the case of protoplast fusion, the cells may be grown in culture medium and screened for appropriate activity. Methods and conditions for culturing the resulting transfected cells and recovering the desired protein (e.g., EPO polypeptide) are known to those skilled in the art and may be modified or optimized according to the specific expression vector and mammalian host cell used as described herein.

[0361] cell In another embodiment, the disclosure features a cell (e.g., a host cell) containing a nucleic acid encoding the EPO polypeptide described herein. In one embodiment, the host cell contains a nucleic acid encoding the amino acid sequence provided in Table 2, or a substantially homologous sequence (e.g., a sequence identical to it by at least about 80%, 85%, 90%, 95%, or 99% or more), or a portion of one of such sequences. In one embodiment, the host cell is genetically engineered to contain a nucleic acid encoding the EPO polypeptide described herein. In one embodiment, host cells are genetically engineered to contain nucleic acids encoding EPO-1.1, EPO-1.2, EPO-1.3, EPO-1.4, EPO-1.5, EPO-2.1, EPO-2.2, EPO-2.3, EPO-3.1, EPO-3.2, EPO-3.3, EPO-4.1, EPO-4.2, EPO-4.3, EPO-5.1, EPO-5.2, or EPO-6.1, or functional fragments thereof.

[0362] In one embodiment, a host cell is genetically engineered using an expression cassette. The term “expression cassette” refers to a nucleotide sequence that can be adapted to express a gene in a host cell. An expression cassette may include a promoter, an open reading frame with or without introns, and a termination signal. Additional factors necessary or useful for expression, such as an inducible promoter, may also be used. In one embodiment, the host cell includes the vector described herein.

[0363] The cells (e.g., host cells) may be, in particular, eukaryotic cells, bacterial cells, insect cells, or human cells. Suitable eukaryotic cells include, in particular, Vero cells, HeLa cells, COS cells, CHO cells, HEK 293 cells, BHK cells, and MDCKII cells. Suitable insect cells include, but are not limited to, Sf9 cells. Suitable bacterial cells include, in particular, Escherichia coli (E. coli) cells. In one embodiment, the cells (e.g., host cells) are isolated cells. In one embodiment, the cells (e.g., host cells) are E. coli cells. In one embodiment, the cells (e.g., host cells) are mammalian cells (e.g., human cells). In one embodiment, the cells (e.g., host cells) are human cells. In one embodiment, the cells (e.g., host cells) are derived from a primary embryonic human kidney. In one embodiment, the cells (e.g., host cells) are FreeStyle 293-F cells.

[0364] EPO variant D The EPO polypeptides and pharmaceutical compositions disclosed herein have therapeutic, prophylactic, and / or diagnostic utility in vitro, ex vivo, and in vivo.

[0365] In one embodiment, the EPO polypeptide modulates (e.g., activates) one or more EPO receptors, for example, to stimulate erythrocyte production. For example, these EPO polypeptides can be administered to cells in culture in vitro or ex vivo, or to a subject, such as a human subject, for example, in vivo, to modulate (e.g., activate) one or more EPO receptors. In one embodiment, the EPO polypeptide stimulates erythrocyte production by activating or substantially activating an EPO receptor, such as a human EPO receptor, for example, to form red blood cells, stimulate hemoglobin C synthesis, and / or increase hematocrit levels. Accordingly, in one aspect, the Disclosure provides a method for treating or preventing a disorder in a subject, such as a disorder described herein (e.g., anemia), comprising administering the EPO polypeptide described herein to the subject so that the disorder is treated or prevented. For example, this disclosure provides a method for treating or preventing a disorder, for example, a disorder described herein, for example, an EPO-related disorder (e.g., EPO deficiency) or anemia, for example, an EPO-related anemia or disorder (e.g., EPO deficiency), which includes contacting cells in culture, for example in vitro or ex vivo, or administering the EPO polypeptide described herein, for example in vivo.

[0366] In one embodiment, the EPO polypeptide exhibits reduced binding affinity to one or more class II MHC alleles (e.g., HLA-DRB1*09) compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). For example, the binding affinity to one or more class II MHC alleles (e.g., HLA-DRB1*09) is reduced by approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more compared to a reference EPO polypeptide (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein). In one embodiment, the EPO polypeptide has no binding affinity to one or more class II MHC alleles (e.g., HLA-DRB1*09). For example, these EPO polypeptides can be administered in culture, in vitro, or ex vivo to immune cells (e.g., antigen-presenting cells and / or T cells), or to a subject, e.g., a human subject, e.g., in vivo, without inducing an immune response, or to induce a reduced immune response compared to a reference EPO polypeptide or preparation (e.g., wild-type or naturally occurring EPO polypeptide, BRP for EPO, or a modified EPO polypeptide lacking one or more (e.g., all) of the mutations described herein), e.g., in vivo. Accordingly, in one embodiment, the Disclosure provides a method for treating or preventing a disorder in a subject, e.g., a disorder described herein (e.g., pure red cell aplasia), comprising administering the subject an EPO polypeptide described herein. For example, this disclosure provides a method for treating or preventing a disorder, for example a disorder described herein, for example an EPO-related disorder (e.g., EPO deficiency), for example pure red cell aplasia, by contacting cells in culture, for example in vitro or ex vivo, or by administering the EPO polypeptide described herein, for example in vivo.

[0367] As used herein, the term “subject” is intended to include humans and non-human animals. In one embodiment, the subject is a human subject, for example, a human patient having EPO-related anemia or disorder (e.g., EPO deficiency) or at risk of having EPO-related anemia or disorder (e.g., EPO deficiency as described herein). The term “non-human animal” includes mammals and non-mammals, for example, non-human primates. In one embodiment, the subject is a human. The methods and compositions described herein are suitable for treating human patients having EPO-related anemia or disorder (e.g., EPO deficiency) as described herein. Patients having EPO-related anemia or disorder (e.g., EPO deficiency) as described herein include patients who have developed EPO-related anemia or disorder (e.g., EPO deficiency) as described herein but are asymptomatic (at least temporarily), patients who have exhibited symptoms of EPO-related anemia or disorder (e.g., EPO deficiency) as described herein, or patients who have anemia-related disorder or EPO-related disorder (e.g., EPO deficiency) as described herein.

[0368] In one embodiment, the EPO-related disorder (e.g., EPO deficiency-related disorder) is pure red cell aplasia (PRCA), for example, antibody-positive PRCA.

[0369] In one embodiment, the subject has anemia or is at risk of developing anemia. In one embodiment, the subject is treated for anemia. In one embodiment, the subject has pure red cell aplasia (PRCA), for example, antibody-positive PRCA, or is at risk of developing it. In one embodiment, the subject is treated for pure red cell aplasia (PRCA), for example, antibody-positive PRCA.

[0370] Methods for treating or preventing disorders The EPO polypeptides described herein (e.g., EPO variants) can be used to treat or prevent EPO-related disorders, such as anemia and / or disorders associated with EPO deficiency, or their symptoms.

[0371] In one embodiment, the disorder is associated with EPO deficiency. In one embodiment, the disorder is associated with or mediated by EPO. In one embodiment, the EPO polypeptide is used to treat subjects having or at risk of developing the disorder described herein.

[0372] Exemplary disorders, such as those associated with or mediated by EPO, include, but are not limited to, anemia (e.g., anemia associated with renal failure; chronic kidney disease; chronic inflammation; cancer; HIV or AIDS; chemotherapy (e.g., cis-platinum-induced anemia); AIDS or HIV therapy (e.g., AZT therapy); radiotherapy; and bone marrow transplantation), pure red cell aplasia (PRCA), iron storage disorders, non-lithium anemia, excessive cytosis, excessive blood loss, thalassemia, sickle cell disease, paroxysmal nocturnal hemoglobinuria, cystic fibrosis, diabetic nephropathy, sepsis, cerebral hypoxia or ischemia, rheumatic diseases, myelodysplastic syndromes, congestive heart failure, Gaucher disease, or Castleman disease.

[0373] The EPO polypeptides described herein are typically administered at a frequency that maintains therapeutically effective levels and / or activity of the EPO polypeptide in the patient's system until the patient recovers. In one embodiment, the EPO polypeptide is administered at a frequency that maintains therapeutically effective levels of the EPO polypeptide in the patient's system for the duration of the patient's life. In one embodiment, the EPO polypeptide is administered at a frequency that maintains a sufficient level of hemoglobin in the patient's blood (e.g., greater than 10 g / dL, e.g., greater than 11, 12, 13, 14 or 15 g / dL, e.g., about 12–15.5 g / dL in women, or about 13.5–17.5 g / dL in men). In one embodiment, the EPO polypeptide is administered every 1, 2, 3, 4, 5, 6 or 7 days, every 1, 2, 3, 4, 5 or 6 weeks, or every 1, 2, 3, 4, 5 or 6 months.

[0374] Methods for administering various EPO polypeptides are known in the art and are described below. The appropriate dose of the EPO polypeptide used depends on the age and weight of the subject and the specific composition used.

[0375] In one embodiment, EPO polypeptide is administered intravenously to a subject (e.g., a human subject). In another embodiment, EPO polypeptide is administered subcutaneously to a subject (e.g., a human subject). In another embodiment, EPO polypeptide is administered to a subject at a dose between approximately 10 units / kg and 500 units / kg, for example, between approximately 15 units / kg and 400 units / kg, between approximately 20 units / kg and 350 units / kg, between approximately 25 units / kg and 350 units / kg, between approximately 50 units / kg and 300 units / kg, between approximately 75 units / kg and 300 units / kg, between approximately 100 units / kg and 300 units / kg, between approximately 100 units / kg and 250 units / kg, between approximately 150 units / kg and 250 units / kg, between approximately 50 units / kg and 150 units / kg, or between approximately 50 units / kg and 100 units / kg. In one embodiment, EPO polypeptide is administered to the subject in a fixed dose of approximately 1,000 to 60,000 units, for example, approximately 2,000 to 40,000 units, approximately 3,000 to 40,000 units, approximately 4,000 to 40,000 units, approximately 10,000 to 40,000 units, approximately 20,000 to 30,000 units, or approximately 30,000 to 40,000 units. In one embodiment, EPO polypeptide is administered once a week, twice a week, three times a week, once every two weeks, once every three weeks, once every four weeks, once every eight weeks, once a month, once every two months, once every three months, or once every six months.

[0376] erythroblastic aplasia (PRCA) The EPO polypeptides described herein can be used to treat or prevent pure red cell aplasia (PRCA).

[0377] PRCA is a type of anemia associated with several causes, including viral infection, immunological involvement, pregnancy, precancerous tumors, toxic exposure, and drug effects. PRCA symptoms are generally characterized by very low levels of reticulocytes and erythrocyte progenitor cells, while other blood cell parameters are relatively normal. rHuEPO-associated PRCA has distinct features, for example, severe rHuEPO resistance, transfusion dependence, elevated serum ferritin, absence of erythrocyte progenitor cells, and the presence of anti-rHuEPO antibodies in the bone marrow (see, e.g., Means, RT, Jr. Blood (2016) 128:2504-2509; Pollock, C. et al. Clin J Am Soc Nephrol (2008) 3:193-199). EPO-associated PRCA outbreaks are a significant burden on affected populations worldwide, particularly in countries like Thailand (see, for example, Praditpornsilpa, K. et al. Nephrol Dial Transplant (2009) 24:1545-1549).

[0378] The number of reported cases of PRCA caused by the expression of neutralizing antibodies against endogenous EPO and recombinant erythropoiesis-promoting agents (ESAs) is increasing worldwide (e.g., Asari A. et al. J. Am. Soc. Nephrol. (2004) 15:2204-2207; Boven K. et al. Kidney Int. (2005) 67:2346-2353; Casadevall, N. et al. N. Engl. J. Med. (2002) 346:469-475; Howman, R. Nephrol. Dial. Transplant (2007) 22:1462-1464; Kruger, A. Nephrol. Dial. Transplant (2003) 18:1033-1034; Lacreta, GJBras. Nephrol. (2019) 41:145-151; and See Sia, C. Ann Acad Med Singapore (2020) 49:46-48). These cases of PRCA are particularly common in patients receiving rHuEPO for the treatment of CKD-related anemia. While we do not wish to be bound by theory, the expression of autoantibodies against endogenous EPO is rare in patients who have not been treated with ESA, but it is thought that anti-rHuEPO neutralizing antibodies may cross-react with endogenous EPO.

[0379] While we do not wish to be bound by theory, in one embodiment, the immunogenic antibody response activated by rHuEPO is thought to be T cell-dependent (e.g., Pollock, C., cited above; Mazor, R., et al. Am J Pathol (2018) 188:1736-1743), and involves (i) internalization of the antigen by professional antigen-presenting cells (APCs) such as dendritic cells (DCs); (ii) processing of the antigen into peptides (epitopes) by mature APCs and presentation to naive T cells by major histocompatibility complex (MHC) class II molecules on the surface of APCs; and (iii) T cell receptor (TCR) and MHC (iv) Interaction with the II-epitope complex; (v) Activation of T cells to release cytokines for B cell activation; (v) Recognition of the bound antigen by B cells via specific T cell epitope / MHC:TCR interaction; (vi) Stimulation of B cells by T cells for cytokine delivery and proliferation and maturation toward plasma cells; and (vii) Steps of antibody production after differentiation of B cells into clonal proliferation and antibody-secreting plasma cells.

[0380] A study on the gene frequency distribution of HLA-A, -B, -DR, and -DQ alleles in Thai patients with proven anti-rHuEPO-associated PRCA demonstrated an association between HLA-DRB1*09 and the risk of anti-rHuEPO-associated PRCA, compared to the gene frequencies of HLA alleles in subjects on the kidney transplant waiting list (e.g., subjects with chronic kidney disease) and subjects in the national stem cell donor registry (e.g., the normal population). This study also showed that all subjects with PRCA expressing the HLA-DRB1*09 allele also expressed the HLA-DQB1*03:09 allele (see, for example, Praditpornsilpa). While we do not wish to be bound by theory, it is thought that the higher frequency of the DRB1*09 allele in the Thai population (approximately 10 times higher than in other regions) may contribute to the higher prevalence of anti-rHuEPO-associated PRCA.

[0381] Pharmaceutical compositions and kits In another embodiment, the present disclosure features a composition comprising the EPO polypeptide described herein, for example, a pharmaceutically acceptable composition, formulated with a pharmaceutically acceptable carrier.

[0382] As used herein, “pharmaceutically acceptable carrier” includes any physiologically compatible solvent, dispersion medium, isotonic agent, and absorption retarder. The carrier may be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, spinal, or dermal administration (e.g., by injection or infusion). In one embodiment, less than about 5% of the EPO polypeptide in the pharmaceutical composition, e.g., about 4%, 3%, 2%, or less than 1%, are present as aggregates. In one embodiment, the level of aggregates is determined by chromatography, e.g., high-speed size exclusion chromatography (HP-SEC).

[0383] The compositions described herein may be in various forms. These include, for example, liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injectable and injectable solutions), dispersions or suspensions, liposomes, and suppositories. The appropriate form depends on the intended mode of administration and therapeutic use. A typical appropriate composition is in the form of an injectable or injectable solution. One appropriate mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In one embodiment, the EPO polypeptide is administered by intravenous infusion or injection. In one embodiment, the EPO polypeptide is administered by subcutaneous injection. In one embodiment, the EPO polypeptide is administered by intramuscular injection.

[0384] As used herein, the terms “parenteral administration” and “administered parenterally” typically refer to modes of administration other than enteral and topical administration by injection, and include, but are not limited to, intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injections and infusions.

[0385] Therapeutic compositions typically must be sterile and stable under manufacturing and storage conditions. Compositions can be formulated as solutions, microemulsions, dispersions, liposomes, or other ordered structures suitable for high protein (e.g., EPO polypeptide) concentrations. Sterile injectable solutions can be prepared by incorporating the required amount of the active compound (e.g., EPO polypeptide) with one or a combination of the components listed above, as needed, into a suitable solvent, followed by filtration sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other necessary components from those listed above. For sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze-drying, which yield powders of the active ingredient and any additional desired components from its pre-sterilized filtered solution. Appropriate fluidity of the solution can be maintained, for example, by the use of a coating such as lecithin, maintaining the required particle size in the case of dispersions, and by the use of surfactants. Sustained absorption of the injectable composition can be achieved by including absorption-delaying agents, such as monostearate and gelatin, in the composition.

[0386] The EPO polypeptides described herein can be administered by a variety of methods. Some are known in the art, and for many therapeutic, prophylactic, or diagnostic applications, suitable routes / modes of administration are intravenous injection or infusion, or subcutaneous injection. As will be understood by those skilled in the art, the route and / or mode of administration varies depending on the desired outcome. In one embodiment, the EPO polypeptide can be prepared in a controlled-release formulation including a carrier that protects the protein from rapid release, such as an implant, a transdermal patch, and a microencapsulated delivery system. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyacid anhydride, polyglycolic acid, collagen, polyoltoesters, and polylactic acid can be used. Many methods for preparing such formulations are patented or generally known to those skilled in the art. See, for example, Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0387] In one embodiment, the EPO polypeptide can be administered orally, for example, with an inert diluent or an absorbable food carrier. The EPO polypeptide (and other components as needed) may also be encapsulated in hard-shell or soft-shell gelatin capsules, compressed into tablets, or directly incorporated into the target meal. For oral therapeutic administration, the EPO polypeptide can be incorporated with excipients and used in the form of ingestible tablets, oral tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, etc. To administer EPO by means other than parenteral administration, it may be necessary to coat the protein with a material to prevent its inactivation, or to administer the protein simultaneously with a material to prevent its inactivation. Therapeutic, prophylactic, or diagnostic compositions can also be administered with medical devices, several of which are known in the art. In one embodiment, the EPO polypeptide is administered in a composition comprising one or more binders, fillers, lubricants, disintegrants, wetting agents, suspending agents, emulsifiers, non-aqueous vehicles, and preservatives, such as maltose or magnesium stearate.

[0388] The administration regimen can be adjusted to provide a desired response (e.g., a therapeutic, prophylactic, or diagnostic response). For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the treatment situation. For ease of administration and uniformity of dosage, it is particularly advantageous to formulate parenteral compositions in dosage unit forms. As used herein, a dosage unit form refers to a physically distinct unit suitable as a unit dose for the subject to be treated, each unit containing a predetermined amount of the active compound calculated to associate with the required pharmaceutically acceptable carrier to produce the desired therapeutic effect. The specifications of the unit dosage form are determined by and directly depend on (a) the inherent characteristics of the EPO polypeptide and the specific therapeutic, prophylactic, or diagnostic effect to be achieved, and (b) the limitations inherent in the techniques for formulating such EPO polypeptides for the treatment of susceptibility in an individual.

[0389] An exemplary, non-limiting range of therapeutically, prophylactically, or diagnostically effective doses of EPO polypeptide is approximately 10 to 500 units per kg of body weight, e.g., approximately 15 to 400 units / kg, 20 to 350 units / kg, 25 to 350 units / kg, 50 to 300 units / kg, 75 to 300 units / kg, 100 to 300 units / kg, 100 to 250 units / kg, 150 to 250 units / kg, 50 to 150 units / kg, or 50 to 100 units / kg. Note that the dosage may vary depending on the type and severity of the condition being alleviated. It should be further understood that for any particular subject, a specific dosing regimen should be adjusted over time in accordance with the individual needs and the professional judgment of the person administering or supervising the administration of the composition, and that the dosing ranges described herein are illustrative only and are not intended to limit the scope or implementation of the claimed composition.

[0390] The pharmaceutical compositions described herein may contain a "therapeutic effective amount" or a "preventive effective amount" of the EPO polypeptide described herein.

[0391] The “therapeutic effective dose” refers to the amount effective in the required dosage and duration to achieve the desired therapeutic outcome. The therapeutic effective dose of EPO polypeptide may vary depending on factors such as the individual’s disease state, age, sex, and weight, as well as the EPO polypeptide’s ability to induce the desired response in the individual. The therapeutic effective dose is also the amount in which any toxic or adverse effects of the EPO polypeptide outweigh the therapeutically beneficial effects. The “therapeutic effective dose” typically increases a measurable parameter by at least about 5%, e.g., at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 60%, or at least about 80%, compared to an untreated subject. The measurable parameter may be, for example, hemoglobin level. For example, the EPO polypeptide described herein can be administered to achieve a hemoglobin level greater than about 10 g / dL, e.g., greater than about 11 g / L, about 12 g / L, about 13 g / L, about 14 g / L, about 15 g / L, about 16 g / L, or about 17 g / L or higher. The ability of EPO polypeptides to increase measurable parameters can be evaluated in animal model systems to predict their effectiveness in treating or preventing anemia. Alternatively, this property of a composition can be evaluated by examining the ability of EPO polypeptides to activate EPO receptors, for example, by measuring TF-1 cell proliferation using in vitro assays.

[0392] The "prophylactic effective dose" refers to the amount that is effective in the required dosage and duration to achieve the desired preventive outcome. Typically, the prophylactic effective dose is less than the therapeutic effective dose, as prophylactic doses are used for subjects before or in the early stages of disease.

[0393] Kits containing the EPO polypeptide described herein are also included in this disclosure. The kits may include one or more other elements, including: instructions for use; other reagents, e.g., labels, therapeutics, or agents useful for chelating or otherwise coupling the EPO polypeptide to the label or therapeutic, or to a radioprotective composition; apparatus or other materials for preparing the EPO polypeptide for administration; a pharmaceutically acceptable carrier; and apparatus or other materials for administration to a subject.

[0394] Combination therapy The EPO polypeptides described herein can be used in combination with other therapeutic agents. For example, a combination therapy may include one or more additional therapeutic agents, e.g., one or more additional therapeutic agents described herein, and an EPO polypeptide that is co-formulated and / or co-administered. In other embodiments, the EPO polypeptide is administered in combination with other therapeutic procedures, e.g., other therapeutic procedures described herein. Such combination therapies may advantageously utilize lower doses of the therapeutic agents administered, and thus avoid potential toxicity or complications associated with various monotherapies.

[0395] As used herein, “administered in combination” means that two (or more) different treatments are delivered to the subject before or during the subject’s suffering due to the disorder. In one embodiment, two or more treatments are delivered prophylactically, for example, before the subject has or is diagnosed with the disorder. In another embodiment, two or more treatments are delivered after the subject has developed or has been diagnosed with the disorder. In one embodiment, there is overlap because the delivery of one treatment is still taking place when the delivery of the second treatment begins. This may be referred to herein as “simultaneous” or “concurrent delivery.” In other embodiments, the delivery of one treatment is completed before the delivery of the other treatment begins. In any one embodiment, the treatments are more effective due to combined administration. For example, the second treatment may produce an equivalent effect with fewer treatments than would be seen if the second treatment were administered in the absence of the first treatment, or if a similar situation were seen with the first treatment, or the second treatment may provide a greater reduction in symptoms. In one embodiment, the delivery is such that the reduction in other parameters related to the symptom or disorder is greater than that observed when one treatment is delivered in the absence of the other. The effects of two or more treatments may be partially additive, fully additive, or greater than additive. In one embodiment, the effects of two or more treatments may be synergistic. The delivery may be such that the effect of the first treatment delivered is still detectable when the second treatment is delivered.

[0396] In one embodiment, the additional agent is a second EPO polypeptide, for example, an EPO polypeptide different from the first EPO polypeptide. Examples of EPO polypeptides that can be used in combination include, but are not limited to, any combination of the EPO polypeptides described herein, such as those listed in Table 2.

[0397] In one embodiment, the EPO polypeptide is administered in combination with a second treatment to treat or prevent diseases or disorders associated with or mediated by EPO, such as anemia (e.g., anemia associated with renal failure, chronic inflammation, cancer, or HIV or AIDS), thalassemia, sickle cell disease, anemia associated with chemotherapy (e.g., cis-platinum-induced anemia), anemia associated with radiotherapy, anemia associated with bone marrow transplantation, iron storage disorders, aplastic anemia, excessive hematopoiesis, excessive blood loss, anemia associated with AIDS or HIV therapy (e.g., AZT therapy), paroxysmal nocturnal hemoglobinuria, cystic fibrosis, diabetic nephropathy, sepsis, cerebral hypoxia or ischemia, rheumatic diseases, myelodysplastic syndromes, congestive heart failure, Gaucher disease, or Castleman disease.

[0398] Examples of therapeutic methods that can be used in combination with the EPO polypeptides or compositions described herein include, for example, hemoglobin, supplemental iron (e.g., elemental iron; ferric or ferrous salts, or compositions thereof, e.g., ferrous sulfate, ferrous gluconate, ferrous fumarate; iron dextran; heme iron polypeptide, e.g., PROFERRIN®), cytokines, lymphokines, interleukins, and colony-stimulating factors including hematopoietic growth factors (e.g., interleukin-1β (IL-1), interleukin-2 (IL-2), interleukin-3 (IL-1)). EPO polypeptides may include L-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-9 (IL-9), interferon-β (IFN-β), interferon-gamma (IFN-γ), granulocyte colony-stimulating factor (GM-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), thrombopoietin (TPO), leukemia inhibitor (LIF), stem cell factor (SCF), oncostatin M (OSM), and vascular endothelial growth factor (VEGF). Furthermore, the EPO polypeptides or compositions described herein may be used in combination with other EPO polypeptides, such as recombinant EPO polypeptides. Non-exclusive examples of recombinant EPO polypeptides include epoetin alpha (e.g., EPOGEN®, EPOADE®, EPOPEN®, EPOXITIN®, EPREX®, ERYPRO®, ESPO®, GLOBUREN®, PROCRIT®), epoetin beta (e.g., EPOCH®, EPOGIN®, ERANTIN®, ERITROGEN®, MAROGEN®, NEORECORMON®, RECORMON®), epoetin omega (e.g., EPOMAX®, HEMAX®), epoetin delta (e.g., DYNEPO®), and darbepoetin alpha (e.g., ARANESP®).EPO polypeptides can also be combined with serial erythropoietin receptor activator (CERA) or synthetic erythropoiesis-producing protein (SEP). In one embodiment, EPO polypeptides are used in combination with other therapeutic agents such as chemotherapeutic agents, hormones, photosensitizers, radionuclides, toxins, antimetabolites, signaling modulators, antibodies (e.g., anti-cancer antibodies), peptides or oligopeptides (e.g., anti-cancer oligopeptides), oligonucleotides (e.g., anti-cancer oligonucleotides), or angiogenesis inhibitors. [Examples]

[0399] Examples are provided below to allow for a more complete understanding of the disclosures contained herein. These examples are provided for illustrative purposes only and are not intended to limit the scope unless otherwise specified. Therefore, this disclosure should not be construed as being limited in any way to these examples, but rather as encompassing all variations that become apparent as a result of the teachings provided herein.

[0400] In the following example, computational design was used to screen for immunogenicity hotspots recognized, for example, by HLA-DRB1*09, and 17 mutants were predicted that would have one to four mutations that would reduce affinity for the allele without disrupting structural integrity and bioactivity. Five of the 17 mutants were found to be less immunogenic in vitro while retaining bioactivity similar to or slightly reduced to that of reference recombinant human EPO (rHuEPO). These engineered proteins are rHuEPO-dependent and could be used to treat patients expressing the HLA-DRB1*09 allele.

[0401] Example 1: Design of recombinant human EPO variant MHC Epitope Predictive Analysis Computational evaluations were performed to predict mutations in the erythropoietin (EPO) amino acid sequence that disrupt binding to the MHC II allele while maintaining protein structure and binding to the EPO receptor. Specifically, an in silico tool (NetMHCII 2.2) was used to predict the amino acid residues involved in the binding between the EPO epitope and the major histocompatibility complex (MHC) class II allele HLA-DRB 1*09-DQB1*03:09 (Jensen et al. Immunology (2018), 154:394-406). The five core binding sites were predicted to be VLRGQALLV (SEQ ID NO: 37) (positions 74-82), LRSLTTLLR (SEQ ID NO: 38) (positions 102-110), LLRALGAQK (SEQ ID NO: 39) (positions 108-116), FRVYSNFLR (SEQ ID NO: 40) (positions 142-150), and YSNFLRGKL (SEQ ID NO: 41) (positions 145-153), which mapped to three different non-overlapping regions (residues 74-82 (VLRGQALLV (SEQ ID NO: 37)), 102-116 (LRSLTTLLRALGAQK (SEQ ID NO: 44)), and 142-153 (FRVYSNFLRGKL (SEQ ID NO: 45))).

[0402] The predicted alleles overlapped with the sites recognized by the two cell surface erythropoietin receptors inferred from the co-crystal structure (PDB:1EER). Known sites neutralizing anti-EPO antibodies from the literature were also mapped. For example, Figure 1A provides the amino acid sequence of EPO, with the receptor contact site (PDB:1 EER) shown in bold and the region predicted by NetMHCII 2.2 for binding to the HLA-DRB1*09-DQB1*03:09 allele in shaded areas. The site recognized by the neutralizing antibody is underlined. Sites considered for amino acid modification are indicated with an asterisk above. Furthermore, Figure 1B provides an example of a network of interacting hydrophobic amino acids containing two of the allele binding sites 74 and 102. Modifications to 74 and / or 102 were then compensated for by appropriate substitutions at other locations in this network.

[0403] Modification of residues in the predicted allele (allele) binding region To preserve the biological activity of the EPO variant, modifications to the predicted allele-binding region were designed to reduce human leukocyte antigen (HLA) and neutralize antibody binding, while avoiding modifications to residues involved in the EPO-R binding interface or structural integrity of the EPO polypeptide, such as residues located within the highly networked helix (BCD) of the alpha helical bundle (Figure 1B). Specifically, regions 102-116 and 142-153 that overlap with or are adjacent to known neutralizing antibody sites were selected, including a total of 25 sites: 74, 75, 76, 77, 79, 80, 81, 82, 102, 105, 106, 109, 111, 112, 113, 114, 115, 116, 142, 145, 146, 148, 149, 152, and 153 (Figure 1A). Non-receptor-binding site (non-RBS) residues were selected for modification, and interatomic contacts were optimized using a variation of the EPCN method (Robinson et al. Cell (2015) 162:493-504). Seventeen EPO variants with HLA affinity disruption designs were devised, as shown in Table 2.

[0404] Example 2: Expression and purification of EPO variants Next, the EPO variants designed in Example 1 and shown in Table 2 were recombinantly expressed and purified using the following procedure.

[0405] Plasmid production and preparation Using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies), a pcDNA 3.3 expression vector containing a sequence encoding an EPO variant with only one mutation / substitution site was constructed. Sequences encoding EPO variants with two or more mutation / substitution sites were generated using gene synthesis, cloned into the pcDNA 3.3 expression vector, and transformed into Escherichia coli (E. coli) (DNA2.0). The purified plasmid was subjected to DNA sequencing (Genewiz) to confirm the mutations.

[0406] Protein expression and purification A purified pcDNA 3.3 expression vector containing a sequence encoding EPO wild-type (EPO-WT) or an EPO variant was transiently transfected into FreeStyle® 293-F cells using 25kD linear polyethyleneimine (Polysciences). After 6 days, the EPO polypeptide was purified from the culture supernatant using a Hitrap Blue HP column (GE Healthcare), eluted with 1.5M NaCl, and buffer-replaced with 20mM Tris-HCl (pH 8.45). Next, the sample was loaded onto a Hitrap Q HP column (GE Healthcare), washed with 20mM sodium acetate (pH 4), and then washed a second time with 20mM Tris. Subsequently, the EPO polypeptide was eluted with 1M NaCl, and the purified EPO polypeptide was buffer-replaced with storage buffer (50mM sodium phosphate buffer, pH 7, 1.5% glycine, and 0.003% Tween-20).

[0407] Cell culture: FREESTYLE® 293-F cells (Invitrogen) were cultured in FreeStyle 293 expression medium (Invitrogen) at 37°C under 8% CO2 using a 130 RPM shaker. Human erythroleukemia cell line TF-1 (ATCC) was cultured in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS, 1% Pen-strep, and 2 ng / mL GM-CSF at 37°C under 5% CO2.

[0408] Example 3: Characterization of EPO variants Next, the EPO variant obtained in Example 2 was quantified, and its characteristics were determined according to the following procedure.

[0409] Quantitative determination of EPO polypeptide A sandwich ELISA was developed for the quantification of both wild-type and variant EPO proteins. A pre-absorbed Maxisorp 96-well plate (Nunc) was used, and 2.5 μg / mL of capture antibody (mouse monoclonal IgG against human EPO) was added to phosphate-buffered saline (PBS). 2A The plates were coated with MAB 2871 (R&D Systems) and incubated overnight at 4°C. The plates were washed three times with PBS and a blocking solution of 1% BSA and 0.05% Tween (PBST) in PBS was added. The plates were incubated at room temperature for 1 hour and washed with PBST. A standard curve was created using the biological reference preparation (BRP) of EPO Batch 4 (European Directorate for the Quality of Medicines & Health Care European Pharmacopoeia, France; Burns et al. (previously cited)). Serial dilutions (2.5-fold) of the EPO standard or EPO sample were achieved at 10,000 international units (IU) or the starting concentration of the undiluted concentration, respectively. Dilutions were performed in PBST in two series. Both the BRP and the sample were incubated at room temperature for 2 hours and then washed with PBST. A primary antibody (rabbit polyclonal IgG against human EPO, AB-286-NA; R&D Systems) at a concentration of 1 μg / mL in PBST was added, the plate was incubated at room temperature for 1 hour, and washed with PBST. Subsequently, a secondary antibody (goat polyclonal secondary Ab-H&L (HRP), pre-absorbed, ab97080; Abcam) in PBST was added at 0.1 μg / mL, incubated at room temperature for 1 hour, and washed with PBST. For detection, TMB substrate (SeraCare) was added. Quenching was achieved by adding 1N sulfuric acid. The plate was read at 450 nm using a microplate reader (Biotek).

[0410] Characterization of EPO polypeptide The protein content of purified EPO polypeptides from FPLC was determined using SDS-PAGE with Coomassie blue staining. Protein samples were separated using a 12% sodium dodecyl sulfate (SDS) polyacrylamide gel, and then separated according to molecular weight at a constant voltage of 175 for 1.5 hours. The electrophoretic gels were stained with INSTANTBLUE® protein stain (Expedeon). The purity of the protein bands was analyzed by measuring the band intensity of each lane using the ImageJ program (Schneider et al. Nat. Methods (2012) 9:671-675). The purity of the purified proteins was 94–99%. The sizes of deglycosylated and glycosylated EPO polypeptides were estimated to be 30.6 kDa and 36–40 kDa, respectively. Both BRP, purified EPO-WT, and EPO variants showed the expected molecular weights.

[0411] Next, Western blot analysis using anti-EPO antibodies was performed to confirm protein identity. Proteins from the SDS-PAGE gel were transferred to a nitrocellulose membrane (Bio-Rad), and the membrane was incubated with rabbit polyclonal IgG, human EPO, and AB-286-NA (R&D Systems). Subsequently, it was incubated with donkey-derived ECL® anti-rabbit IgG, peroxidase-binding species-specific whole antibody, and NA934V (GE Healthcare). The signal was developed using ECL® Prime Western Blotting Detection Reagent (GE Healthcare). The chemiluminescent signal was detected and analyzed using an ImageQuant LAS 4000 instrument (GE Healthcare). BRP, EPO-WT, and EPO variant proteins all showed positive bands.

[0412] For example, Figures 2A and 2B provide Coomassie blue stained gels (Figure 2A) and Western immunoblotting (Figure 2B) of EPO polypeptides containing EPO standards, wild-type, and mutant proteins after separation according to molecular weight by SDS-PAGE. The materials used were BRP, EPO standards, markers, Precision Plus Protein® Kaleidoscope® Prestained Protein Standards; WT, EPO-WT; 1.2, EPO-1.2 (L70V, V74L, L102I); 3.1, EPO-3.1 (T106A); 3.2, EPO-3.2 (T106G); 3.3, EPO-3.3 (T106H); 4.1, EPO-4.1 (L109A).

[0413] Characterization of EPO isoforms The isoform distribution of EPO polypeptides was determined according to the TD2014EPO technical document outlined by the World Anti-Doping Agency (www.wada-ama.org / en / resources / science-medicine / td2014epo). Purified EPO samples prepared by the method outlined above were buffered with MilliQ water and separated by isoelectric focusing (IEF) gels according to their pI at a pH gradient of 2–6 using a flatbed electrophoresis cell - MultiphorII (GE Healthcare). The electrophoretic samples were then transferred to Armersham Hybond™-P PVDF transfer membranes (GE Healthcare) using a semi-dry Novablot transfer system (GE Healthcare). After blotting, the membranes were treated by Western blotting analysis as described herein.

[0414] Ioform analysis of EPO polypeptides by IEF is shown in Figure 3, including EPO standard, wild-type, and mutant proteins. The isolated bands of proteins represent the number of their existing glycoforms. The distribution of different isoforms of purified EPO polypeptides was compared with that of the EPO standard, BRP. BRP, EPO standard;WT, EPO-WT;1.2,EPO-1.2(L70V, V74L, L102I);3.1,EPO-3.1(T106A);3.2,EPO-3.2(T106G);3.3,EPO-3.3(T106H);4.1,EPO-4.1(L109A).

[0415] The glycoform distributions of BRP and six EPO samples (one wild-type and five mutants) were observed in the basic region of the gel (Figure 3). BRP showed six isoforms as expected. However, the number of isoforms varied among the EPO samples (EPO-3.3 showed six isoforms, EPO-WT, EPO-3.1, and EPO-3.2 showed seven isoforms, while EPO-1.2 and EPO-4.1 showed eight isoforms). EPO-3.1, EPO-3.2, EPO-3.3, and EPO-4.1 showed a shift in their isoform distribution towards basic isoforms. The two most basic bands of these EPO samples were significantly higher than those of EPO-WT. EPO-1.2, on the other hand, showed a similar profile or a slight shift towards acidic isoforms.

[0416] Example 4: In Vitro Bioactivity of EPO Variants The physiological activity of the EPO variant protein obtained in Example 2 (shown in Table 2) was measured using a TF-1 cell line derived from erythroleukemia patients by a cell proliferation assay following the procedure below. Total 2.5 × 10⁶ 4TF-1 cells were plated into a 96-well flat-bottom plate (Nunc). BRP or EPO polypeptide (50 IU / mL) was diluted 3-fold. All dilutions were performed in quadruple packs. After 72 hours of incubation, WST-1 cell proliferation reagent (Roche) was added. The reaction mixture was incubated in 5% CO2 for 4 hours. Absorbance at 450 nm and 690 nm was measured using a microplate reader (Biotek). EC was calculated using a 4-parameter logistic regression function with GEN5™ data analysis software (Biotek). 50 and R 2 The following was calculated. Parallelism analysis was performed to evaluate the relative potency (REP) of the EPO variant relative to EPO-WT. Log dose-response curves for 4-parameter logistic regression were generated using GraphPad Prism 6 (Graphpad Software, Inc.).

[0417] The in vitro bioactivity of selected EPO variants containing TF-1 cells, including EPO-1.2 (L70V, V74L, and L1023I), EPO-3.1 (T106A), EPO-3.2 (T106G), EPO-3.3 (T106H), and EPO-4.1 (L109A), is shown in the logarithmic dose-response curves in Figure 4. All five EPO variants showed lower bioactivity compared to wild-type EPO. In particular, EPO-1.2 and EPO-4.1 had relative bioactivity (REP) of 0.059 (or 5.9% of EPO-WT activity) and 0.032 (or 3.2% of EPO-WT activity), respectively. EPO-3.1 had the highest bioactivity among the EPO variants, with an REP of 0.431 (or 43.1% of EPO-WT activity). EPO-3.2 and EPO-3.3 exhibited the same range of biological activity, with REP values ​​of 0.243 (or 24.3% activity compared to EPO-WT) and 0.229 (or 22.9% activity compared to EPO-WT), respectively.

[0418] Example 5: Immunogenicity of EPO variants The immunogenicity of exemplary EPO variants prepared according to the methods described herein (EPO-WT, EPO-1.2, EPO-3.1, EPO-3.2, EPO-3.3, and EPO-4.1) was tested by the following procedure. As illustrated in Figures 5A–5C, all five EPO variants tested showed lower immunogenicity compared to BRP and wild-type EPO.

[0419] Preparation of peripheral blood mononuclear cells (PBMCs) Blood samples were collected from 50 healthy volunteers in EDTA-treated vacuum tubes (Becton Dickinson). The presence of the HLA-DRB1*09 gene and common infections, including hepatitis B, hepatitis C, syphilis, and HIV, was determined at the Faculty of Medicine, Chulalongkorn University, Thailand. Of the 50 volunteers, 11 (22%) had HLA-DRB1*09, of which 4 were female (36%) and 7 were male (64%). All volunteers, both HLA-DRB1*09 negative and positive, were randomly selected for immunogenicity testing and confirmed to be negative for common infections, including hepatitis B, hepatitis C, syphilis, and HIV. PBMCs were isolated from the blood of 3 HLA-DRB1*09 negative volunteers and 3 HLA-DRB1*09 positive volunteers using IsoPrep solution (Robbins Scientific Corporation).

[0420] Dendritic cell culture and flow cytometry analysis Total PBMCs in complete RPMI medium (3 mL): 10 × 10 6 Cells were seeded in each well of a 6-well plate. After incubation at 37°C under 5% CO2 for 2 hours, precursor dendritic cells (DCs) were separated from other immune cells by adhesion to plastic, and non-adherent cells were identified as CD4. +Cells were collected as a source of T cells. Complete RPMI medium containing GM-CSF (50 ng / mL) and IL-4 (50 ng / mL; ImmunoTools) was added to adherent cells representing precursor dendritic cells (DCs). The cells were incubated, and 75% of the used medium was replaced with fresh medium containing cytokines every two days. Differentiation from precursor DCs to immature DCs was monitored using a BD FACSCANTO® flow cytometer (BD Biosciences) with FITC-conjugated anti-human HLA-DR (ImmunoTools). The rate of immature DC maturation in both groups ranged from 50.7 to 80.4 on day 7 of DC culture.

[0421] Immature DCs were harvested and washed in complete RPMI medium to generate mature DCs as antigen-presenting cells (APCs). Then, a total of 10 5 Cells were seeded in each well of a 24-well plate and incubated (pulsed) for 48 hours with 10 μg / mL of BRP or EPO polypeptide (EPO-WT, EPO-1.2, EPO-3.1, EPO-3.2, EPO-3.3, and EPO-4.1). Immature DCs incubated without protein were used as control DCs (unpulsed DCs).

[0422] CD4 + T cell isolation and activation CD4 + T cells were extracted from the non-adherent cell fraction of PBMCs from the same volunteer who provided monocytes for DC culture, using MACS Human CD4. + Cells were isolated by negative selection using the T cell Isolation Kit (Miltenyi Biotec). The viability was over 90%. EPO-pulsed (mature) DCs and CD4 cells from the same volunteer were used to activate effector immune cells. + T cells were co-cultured in a 1:20 ratio. Positive controls included unpulsed DCs and CD4 cells supplemented with 5 μg / mL anti-human CD3 and 2 μg / mL anti-human CD28 (ImmunoTools). +The study included co-culture of T cells. Background controls included unpulsed DCs and CD4 cells. + The study included co-cultures of T cells alone. All co-cultures were incubated for 4 days in the presence of IL-2 (30 ng / mL) and IL-12 (30 ng / mL) (ImmunoTools), and then harvested.

[0423] The level of interferon-gamma (IFN-γ), which represents the T cell response, was quantified using the Human IFN-γ ELISA Kit (ImmunoTools). Non-pulsed DC cells and CD4 + The level of IFN-γ from co-culture with T cells was considered the background for the T cell response. Statistical comparison of the relative T cell response of EPO polypeptides compared to BRP between the HLA-DRB1*09 negative and positive groups demonstrated that all five EPO variants tested had a significantly lower T cell response in the HLA-DRB1*09 positive group.

[0424] The results of the ex vivo immunogenicity assay of EPO polypeptide are shown in Figures 5A-5C. Mean values ​​from three HLA-DRB1*09-negative volunteers and three HLA-DRB1*09-positive volunteers were combined as either the negative or positive group. Each group was compared to the response to BRP, and the relative response to EPO polypeptide is shown as a percentage (Figure 5A). The bar graph shows the mean ± SEM calculated from three individuals in each group. Asterisks indicate statistical significance based on t-tests (*p≦0.05, **p≦0.01, ***p≦0.001, ****p≦0.0001). IFN-γ levels for each HLA-DRB1*09-positive volunteer are shown in Figure 5B, and HLA-DRB1*09-negative volunteers are shown in Figure 5C. The bar graph shows the mean ± SEM calculated from dual experiments.

[0425] The p-values ​​were 0.0038 for EPO-1.2, 0.000024 for EPO-3.1, 0.000037 for EPO-3.2, 0.00031 for EPO-3.3, and 0.0012 for EPO-4.1. There was no difference in T cell response using EPO-WT in either the HLA-DRB1*09 negative or positive group. In both the HLA-DRB1*09 positive and negative groups, BRP and EPO-WT were able to stimulate T cell responses in the same manner as anti-CD3 / anti-CD28 antibodies. EPO variants, including EPO-1.2, EPO-3.1, EPO-3.2, EPO-3.3, and EPO-4.1, showed a much lower T cell response, with IFN-γ release ranging from 220 to 37,000 pg / mL. While we do not wish to be bound by theory, the differing backgrounds of EPO-specific T cell responses observed in HLA-DRB1*09-positive and HLA-DRB1*09-negative groups may be due to differences in HLA allele (allele) distribution within individuals (see, for example, Praditpornsilpa et al., cited above; and Tangri et al. J.Immunol. (2005) 174:3187-3196).

[0426] Statistical analysis: T-test analysis was performed using GraphPad Prism 6 (Graphpad Software, Inc.). For example, the statistical significance of the relative difference in T cell response between the HLA-DRB1*09 negative and positive groups was determined using the t-test.

[0427] Human subjects: Studies involving human subjects were conducted under protocols approved by the Ethics Review Board of the Chulabhorn Research Institute in Thailand. All volunteers submitted written informed consent.

[0428] Built-in by reference All publications, patents, and accession numbers referenced herein are incorporated herein by reference in whole, as if each individual publication or patent were specifically and individually indicated to be incorporated by reference.

[0429] Equal parts While specific embodiments of this disclosure have been described, the above specification is illustrative and not limiting. By examining this specification and the following claims, many variations of this disclosure will become apparent to those skilled in the art. The entire scope of this disclosure should be determined by referring to the claims, the entire scope of their equivalents, the specification, and such variations. [Sequence Listing Free Text]

[0430] Sequence Listing 3 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 4 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 5 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 6 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 7 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 8 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 9 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 10 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 11 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 12 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 13 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 14 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 15 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 16 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 17 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 18 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 19 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 20 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 21 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 22 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 23 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 24 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 25 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 26 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 27 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 28 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 29 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 30 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 31 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 32 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 33 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 34 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 35 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 36 <223> Description of artificial sequences: Synthetic polynucleotides Sequence Listing 42 <223> Description of artificial sequences: Synthetic polypeptides Sequence Listing 42 <223> Substitution = "A" or "I" Sequence Listing 42 <223> Substitution = "I" or "W" Sequence Listing 42 <223> Substitution = "D", "N", or "V" Sequence Listing 42 <223> Substitution = "V" Sequence Listing 42 <223> Substitution = "D", "L", or "N" Sequence Listing 42 <223> Substitution = "D", "I", "N", "T", or "V" Sequence Listing 42 <223> Substitution = "F" or "S" Sequence Listing 42 <223> Substitution = "A", "G", or "H" Sequence Listing 42 <223> Substitution = "A", "C", or "W" Sequence Listing 42 <223> Substitution = "C" Sequence Listing 42 <223> Replacement = "N" Sequence Listing 42 <223> Substitution = "V" or "W" Sequence Listing 42 <223> Substitution = "Q" Sequence Listing 42 <223> Variant residues specified within a sequence do not take precedence over variant residues in the annotation of a variant position. Sequence Listing 42 <223> For a detailed description of substitutions and preferred embodiments, please refer to the specification filed at the time of application. Sequence Listing 43 <223> Artificial sequence description: Synthetic 6×His tag

Claims

1. An erythropoietin (EPO) molecule comprising a plurality of mutations at a plurality of positions of SEQ ID NO:1, said EPO molecule comprising: (a) mutations at positions corresponding to positions 67 and 102 of SEQ ID NO:1; (b) mutations at positions corresponding to positions 70, 74, and 102 of SEQ ID NO:1; (c) mutations at positions corresponding to positions 67, 74, and 102 of SEQ ID NO:1; (d) mutations at positions corresponding to positions 12, 15, 105, and 149 of SEQ ID NO:1; (e) a mutation at a position corresponding to positions 109 and 114 of SEQ ID NO:1; or (f) mutations at positions corresponding to 102, 105, 106, and 109 of SEQ ID NO:1; An erythropoietin (EPO) molecule comprising:

2. An EPO molecule comprising a mutation at one or more positions of SEQ ID NO:1, said EPO molecule comprising: (a) a mutation at a position corresponding to position 74 of SEQ ID NO:1, wherein the mutation is a V74D substitution; (b) a mutation at a position corresponding to position 106 of SEQ ID NO:1, wherein the mutation is a T106G substitution, or the mutation is a T106H substitution; (c) a mutation at a position corresponding to positions 67 and 102 of SEQ ID NO:1, the mutation being an L67V and an L102V substitution; (d) mutations at positions corresponding to 70, 74, and 102 of SEQ ID NO:1, wherein the mutations are L70V, V74L, and L102I substitutions; (e) mutations at positions corresponding to 67, 74, and 102 of SEQ ID NO:1, wherein the mutations are L67N, V74N, and L102D substitutions or the mutations are L67D, V74D, and L102N substitutions; (f) mutations at positions corresponding to 12, 15, 105, and 149 of SEQ ID NO:1, wherein the mutations are L12A, Y15I, L105F, and L149W substitutions or the mutations are L12I, Y15W, L105S, and L149V substitutions; (g) a mutation at a position corresponding to positions 109 and 114 of SEQ ID NO:1, the mutation being an L109C and an A114C substitution; or (h) mutations at positions corresponding to 102, 105, 106 and 109 of SEQ ID NO: 1, wherein the mutations are L102T, L105S, T106H and L109W substitutions or the mutations are L102T, L105S, T106G and L109W substitutions. The EPO molecule comprising:

3. An EPO molecule described in claim 1 or 2, comprising or consisting of the amino acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:31, or SEQ ID NO:

33. (a) the EPO molecule has reduced immunogenicity in a subject compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; (b) the EPO molecule has the same or substantially the same biological activity as compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; (c) the EPO molecule has a biological activity that is reduced by no more than 25%, 20%, 15%, 10%, 5%, or 2% compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; (d) the EPO molecule can have more glycoforms compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; (e) the EPO molecule has the same or substantially the same serum half-life as compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; (f) the EPO molecule has an increased serum half-life compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; and / or (g) the EPO molecule has a reduced serum half-life compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; An EPO molecule according to any one of claims 1 to 3.

5. (i) the immunogenicity is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to a reference EPO molecule; (ii) the subject possesses an HLA-DRB1*09 allele; (iii) the biological activity is measured in an in vitro TF-1 proliferation assay; (iv) the EPO molecule can have at least 1, 2, 3, 4, or 5 more glycoforms; (v) the EPO molecule has at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% increased serum half-life, or at least a 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10-fold increased serum half-life, compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; and / or (vi) the EPO molecule has a serum half-life that is reduced by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% or less compared to a reference EPO molecule comprising the amino acid sequence of SEQ ID NO:1; The EPO molecule of claim 4. (a) the EPO molecule comprises a moiety that extends the serum half-life of an EPO polypeptide; (b) the EPO molecule is a fusion protein; and / or (c) the EPO molecule comprises an IgG Fc domain; An EPO molecule according to any one of claims 1 to 5.

7. The EPO molecule of claim 6 , wherein the Fc domain is covalently fused to the EPO polypeptide.

8. The EPO molecule of claim 6 or 7, wherein the N-terminus of the Fc domain is covalently fused directly or indirectly to the C-terminus of the EPO polypeptide.

9. A pharmaceutical composition comprising an EPO molecule according to any one of claims 1 to 8 and a pharma- ceutically acceptable carrier.

10. A nucleic acid encoding an EPO molecule according to any one of claims 1 to 8.

11. 11. The nucleic acid of claim 10, comprising the nucleotide sequence of any of SEQ ID NOs: 4, 6, 10, 12, 14, 16, 22, 24, 30, 32, or 34, or a nucleotide sequence which differs therefrom by no more than 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides, or which is at least 80%, 85%, 90%, 95%, 98% or 99% identical thereto.

12. A vector comprising the nucleic acid of claim 10 or 11.

13. The vector of claim 12 , comprising a promoter operably linked to the nucleic acid.

14. A cell comprising a nucleic acid according to claim 10 or 11, or a vector according to claim 12 or 13.

15. A method for producing an EPO molecule comprising culturing a cell according to claim 14 under conditions allowing expression of the EPO polypeptide, thereby producing the EPO molecule.

16. A pharmaceutical composition for use in treating a disorder in a subject, comprising an EPO molecule described in any one of claims 1 to 8.

17. The pharmaceutical composition described in claim 16, wherein the disorder is an EPO-related disorder.

18. The pharmaceutical composition described in claim 16 or 17, wherein the disorder includes an EPO deficiency or abnormality.

19. The pharmaceutical composition of any one of claims 16 to 18, wherein the disorder is anemia.

20. 20. The pharmaceutical composition of claim 19, wherein the anemia is associated with or results from chronic kidney disease or chronic renal failure, zidovudine treatment, chemotherapy, or surgery.

21. A pharmaceutical composition for use in reducing an immunogenic response in a subject, comprising an EPO molecule described in any one of claims 1 to 8.

22. A pharmaceutical composition comprising an EPO molecule according to any one of claims 1 to 8 for use in treating or preventing pure red cell aplasia (PRCA) in a subject.

23. A pharmaceutical composition for use in reducing allogeneic red blood cell (RBC) transfusions in a subject, comprising an EPO molecule according to any one of claims 1 to 8.

24. (a) The subject has chronic kidney disease, HIV infection, or cancer. (b) the subject is receiving or has received zidovudine; (c) the subject is undergoing or has undergone chemotherapy, surgery, or an allogeneic RBC transfusion; (d) the subject has, or has been determined to have, anti-EPO antibodies; and / or (e) the subject has been administered a different recombinant human EPO (rHuEPO), 25. The pharmaceutical composition of claim 24, wherein the different rHuEPO comprises the amino acid sequence of SEQ ID NO:1, and / or administration of the different rHuEPO is discontinued or terminated.